Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal English
Coverage 116,877 Raw stories ingested 12,646 rewritten in CS_CZ • 0 to rewrite (last 2 days).
Agents 7 waiting Pipeline agents
  • FMP Stock News Fetch every minute 51s ago
  • FMP Forex News Fetch every 5 min 51s ago
  • CoinGecko News Fetch every 5 min 51s ago
  • FIO Stock News Fetch every 10 min 9m ago
  • Patria Stock News Fetch every 10 min 9m ago
  • Editorial rewrite Rewrite every minute 51s ago
  • Asset sync Assets every 1 hour 49m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

View
Clear
Details Date Content Source
2026-07-01 12:15 1mo ago
2026-07-01 08:00 1mo ago
Tractor Supply: 3.2% Yield From Chicks, Feed, And More
TSC Tractor Supply
FMP Stock News
Original source text
HomeDividends AnalysisDividend IdeasConsumer 

SummaryTractor Supply Company is a wide-moat rural retailer with a resilient, needs-based business model and strong local market adaptation.TSCO targets 3,200 stores long-term, leveraging a $225 billion addressable market and ongoing digital integration to drive growth and recurring revenue.Shares trade at a discount to a $40 fair value estimate, with 8.9% annual EPS growth expected and a sustainable 3.2% dividend yield.Key risks include store footprint cannibalization and underperformance in the companion animal segment, but localized offerings and loyalty programs strengthen TSCO’s competitive position.Looking for a portfolio of ideas like this one? Members of The Dividend Kings get exclusive access to our subscriber-only portfolios. Learn More » ligora/iStock via Getty Images

Co-authored by Kody's Dividends

We have a nearly annual tradition in my household. Every spring or early summer, we end up getting new chicks to join our flock.

We've been chicken owners now for nearly a decade, and that means as

4.91K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Kody's Dividends, Justin Law, and Rachel Kaufman are part of The Dividend Kings team.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
2026-07-01 12:14 1mo ago
2026-07-01 07:19 1mo ago
Klarna has received a favorable ruling in PriceRunner litigation, awarding damages of $1.97 billion
KLAR Klarna Group
FMP Stock News
Original source text
NEW YORK--(BUSINESS WIRE)--Klarna Group plc (NYSE: KLAR) today announces that the court has ruled in PriceRunner's favor, awarding $1.97 billion in damages in an antitrust case brought by PriceRunner against Google. The award compensates for lost revenue caused by Google's preferential treatment of its own comparison-shopping service over independent price-comparison services, conduct that also drives up costs for consumers. "When markets work well, everyone benefits. Consumers get higher quali.
2026-07-01 12:12 1mo ago
2026-07-01 07:00 1mo ago
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
HROW Harrow Health
FMP Stock News
Original source text
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced the relaunch of BYOOVIZ® (ranibizumab-nuna) in the United States (US), in partnership with Harrow (Nasdaq: HROW). Harrow became responsible for commercialization of BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUCENTIS1 (ranibizumab), and OPUVIZ™ (aflibercept-yszy), a biosimilar referencing EYLEA2 (aflibercept), upon full transition of commercialization rights from Biogen back to Samsung Bioepis by the end of 2025.

Today marks an exciting new chapter for BYOOVIZ in the US. As the first FDA-approved biosimilar to Lucentis, BYOOVIZ has already demonstrated its value in expanding access to critical retinal disease treatments.

Share BYOOVIZ was approved by the U.S. Food and Drug Administration (FDA) in September 2021 as the first ophthalmology biosimilar in the US for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), and Myopic Choroidal Neovascularization (mCNV).3 BYOOVIZ was granted interchangeability designation by the FDA in October 2023.4

Wet AMD affects approximately 1.2% to 1.3% of adults aged 65 and older in the US, with 1.5 million Americans living with the late, vision-threatening stages of the disease.5,6 Over the past two decades, anti-VEGF therapy has become a standard treatment for wet AMD.7 However, cost remains a significant financial burden for ranibizumab and other anti-VEGF treatments in the US.8 Biosimilars are biological products that are highly similar to existing FDA-approved reference products with no clinically meaningful differences in safety, purity, or potency and have the potential to alleviate the financial burden associated with current anti-VEGF therapies.9

“Today marks an exciting new chapter for BYOOVIZ in the US. As the first FDA-approved biosimilar to Lucentis, BYOOVIZ has already demonstrated its value in expanding access to critical retinal disease treatments. With Harrow now leading commercialization efforts, we are reigniting our commitment to ensuring patients and retina specialists across America to have access to this quality-proven, safe and effective biosimilar option,” said Linda Choi MacDonald, Executive Vice President and Global Head of Commercial, Samsung Bioepis. “We believe this relaunch will ultimately help more patients with critical ophthalmic diseases to receive the vision-saving treatments they need.”

In July 2025, Samsung Bioepis entered into partnership with Harrow for commercialization of BYOOVIZ and OPUVIZ in the US. Samsung Bioepis is responsible for development, regulatory registration, and manufacture of the products, while Harrow is responsible for commercialization.

BYOOVIZ was also approved as the first ophthalmology biosimilar by the European Commission and the United Kingdom in August 2021, and in Canada in March 2022. In Europe, Samsung Bioepis is responsible for direct commercialization of BYOOVIZ.

About BYOOVIZ (ranibizumab-nuna)

BYOOVIZ (ranibizumab-nuna) injection, for intravitreal use.
BYOOVIZ (ranibizumab-nuna) is an interchangeable biosimilar to LUCENTIS (ranibizumab injection).
BYOOVIZ, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:
Neovascular (Wet) Age-Related Macular Degeneration (AMD)
Macular Edema Following Retinal Vein Occlusion (RVO)
Myopic Choroidal Neovascularization (mCNV)

Select Important Safety Information

WARNING AND PRECAUTIONS

Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be monitored following the injection.
Increases in intraocular pressure (IOP) have been noted both pre- and post-intravitreal injection.
There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors.

ADVERSE REACTIONS

The most common adverse reactions (reported more frequently in ranibizumab treated subjects than control subjects) are conjunctival hemorrhage, eye pain, vitreous floaters, and increased IOP.

Please see Prescribing Information for BYOOVIZ (ranibizumab-nuna) HERE.

About OPUVIZ (aflibercept-yszy)

OPUVIZ (aflibercept-yszy) injection, for intravitreal use.
OPUVIZ (aflibercept-yszy) is an interchangeable biosimilar to EYLEA (aflibercept).
OPUVIZ is a vascular endothelial growth factor (VEGF) inhibitor, indicated for the treatment of patients with:
Neovascular (Wet) Age-Related Macular Degeneration (AMD)
Macular Edema Following Retinal Vein Occlusion (RVO)
Diabetic Macular Edema (DME)
Diabetic Retinopathy (DR)

Select Important Safety Information

WARNING AND PRECAUTIONS

Endophthalmitis, retinal detachments, and retinal vasculitis with or without occlusion may occur following intravitreal injections. Patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment, or retinal vasculitis without delay and should be managed appropriately.
Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection.
There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors.

ADVERSE REACTIONS

The most common adverse reactions (≥5%) reported in patients receiving aflibercept were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.

Please see Prescribing Information for OPUVIZ (aflibercept-yszy) HERE.

DISCLAIMER

This press release is intended solely for the purpose of sharing the availability of BYOOVIZ in the US. This document should not be construed as medical advice or as an endorsement of any product or treatment. Regulatory approval status and prescribing information may vary by country; please refer to local product information for any medicinal products mentioned herein. Information in this press release may include data on investigational compounds or unapproved indications. Such information is shared for scientific discussion purposes only and does not represent an assertion of safety or efficacy for any unapproved use.
This press release may contain forward-looking statements, including statements regarding clinical development programs, regulatory submissions, potential approvals, and future therapeutic potential. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Forward-looking statements are not guarantees of future performance. Samsung Bioepis undertakes no obligation to update any forward-looking statements contained in this press release.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. As a wholly owned subsidiary of Samsung Epis Holdings, Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, endocrinology and neurology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and diseases of the retina. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

1 Lucentis is a trademark of Genentech, Inc.

2 Eylea is a trademark of Regeneron Pharmaceuticals, Inc.

3 U.S. Food and Drug Administration. FDA Approves First Biosimilar to Treat Macular Degeneration Disease and Other Eye Conditions. Press Release. Sep 20, 2021. Available at: https://www.prnewswire.com/news-releases/fda-approves-first-biosimilar-to-treat-macular-degeneration-disease-and-other-eye-conditions-301380552.html (Accessed June 2026)

4 U.S. Food and Drug Administration. Supplement Approval for Byooviz (ranibizumab-nuna) injection 0.5 mg (10 mg/mL) for intravitreal injection (BLA 761202/S-006). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/761202Orig1s006ltr.pdf (Accessed June 2026)

5 Saundankar V, Borns M, Broderick K, Shah B, Cowburn S, McFadden S, Suehs B. Annual prevalence of geographic atrophy and wet age-related macular degeneration among Medicare Advantage enrollees in a US health plan. J Manag Care Spec Pharm. 2025 Jan;31(1):88-94. doi: 10.18553/jmcp.2025.31.1.88. PMID: 39745845; PMCID: PMC11695844.

6 Center for Disease Control and Prevention. Vision and Eye Health Surveillance System. VEHSS Modeled Estimates: Age-Related Macular Degeneration (AMD). Available at: https://www.cdc.gov/vision-health-data/prevalence-estimates/amd-prevalence.html (Accessed June 2026)

7 Kovach JL, Schwartz SG, Flynn HW Jr, Scott IU. Anti-VEGF Treatment Strategies for Wet AMD. J Ophthalmol. 2012;2012:786870. doi: 10.1155/2012/786870. Epub 2012 Feb 28. PMID: 22523653; PMCID: PMC3317200.

8 Tabano D, Watane A, Gale R, Cox O, Hill SR, Longworth L, Oluboyede Y, Ahmed A, Patel NA. The Economic Burden of Anti-Vascular Endothelial Growth Factor on Patients and Caregivers in the UK, Europe, and North America. Ophthalmol Ther. 2025 Aug;14(8):1869-1892. doi: 10.1007/s40123-025-01180-5. Epub 2025 Jun 28. PMID: 40580375; PMCID: PMC12270987.

9 U.S. Food and Drug Administration. Biosimilars: Overview for Health Care Professionals. Available at: https://www.fda.gov/drugs/biosimilars/overview-health-care-professionals (Accessed June 2026)

More News From Samsung Bioepis Co., Ltd.
2026-07-01 12:12 1mo ago
2026-07-01 07:00 1mo ago
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
HROW Harrow Health
FMP Stock News
Original source text
Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar July 01, 2026 07:00 ET  | Source: Harrow, Inc.

NASHVILLE, Tenn., July 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTISi (ranibizumab) and developed by Samsung Bioepis Co., Ltd.

The launch follows Harrow's exclusive U.S. commercialization agreement with Samsung Bioepis, one of the world's leading biosimilar developers and manufacturers. Through this partnership, Harrow obtained exclusive U.S. rights to commercialize BYOOVIZ and OPUVIZ® (aflibercept-yszy), an FDA-approved biosimilar referencing EYLEAii (aflibercept), further strengthening the Company's position in the rapidly growing retinal biologics market.

BYOOVIZ was approved by the U.S. Food and Drug Administration (FDA) as the first ophthalmology biosimilar in the U.S. for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), and Myopic Choroidal Neovascularization (mCNV). As an FDA-designated interchangeable biosimilar to LUCENTIS, BYOOVIZ provides retina specialists with a clinically proven anti-VEGF therapy that offers confidence, flexibility, and choice in patient care.

The launch of BYOOVIZ marks another important step in the evolution of Harrow's market-leading retina franchise. With an estimated $9 billion U.S. anti-VEGF marketiii and increasing demand for therapies that treat sight-threatening retinal diseases, Harrow continues to build a differentiated portfolio of buy-and-bill products designed specifically for the needs of retina specialists and the patients they serve.

BYOOVIZ joins Harrow's expanding retina franchise, which includes IHEEZO® (chloroprocaine hydrochloride 3% ophthalmic gel), a branded FDA-approved ocular anesthetic indicated for ocular surface anesthesia that is increasingly utilized by retina specialists during intravitreal injection procedures, and TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/ml, a high-trust preservative-free injectable corticosteroid, broadly labeled and increasingly used by retina specialists nationwide. Together, these products enable Harrow to support both the procedural and therapeutic aspects of retinal disease management, providing retina practices with a trusted commercial partner across multiple points of care.

"BYOOVIZ is far more than a product launch—it underscores Harrow's commitment to the U.S. retina community," said Mark L. Baum, Founder, Chairman, and Chief Executive Officer of Harrow. "Over the past several years, we have earned the trust of physicians through products like IHEEZO and TRIESENCE—products a growing number of retina specialists have integrated into their procedural workflows—supported by one of the most experienced and tenured retina teams in the industry. The investments we’ve made in our commercial infrastructure are specifically designed to serve retina specialists, and we intend to keep investing in and growing our retina franchise for years to come. With BYOOVIZ, we will bring our customers an interchangeable ranibizumab biosimilar to a market increasingly focused on both clinical confidence and economic value. Together with exclusive commercialization rights to OPUVIZ in the US, we believe we are creating one of the most compelling retina portfolios in ophthalmology."

“The introduction of BYOOVIZ gives retina specialists another valuable treatment option for our patients,” said Samuel A. Minaker, M.D., vitreoretinal surgeon, Director of Clinical Research at Tyler Retina Consultants. “Many of my patients are treated with LUCENTIS or a LUCENTIS-referenced biosimilar; however, we have found that access to supply has not always been assured, with products coming in and out of availability more recently. What gives me additional confidence in BYOOVIZ is its interchangeability designation, supported by data showing no clinically meaningful differences between the biosimilar and reference product when patients switch between therapies. Just as importantly, it's exciting to see this product return to the market through a commercial partner like Harrow that has already earned credibility in my practice and within the retina community. Harrow understands the needs of retina practices, has demonstrated a commitment to supporting physicians and patients, and brings a level of confidence that makes BYOOVIZ a welcome addition to the treatment options available for my patients.”

“I’ve had the opportunity to work with Harrow on several ophthalmic products,” said Seenu M. Hariprasad, M.D., Chair of Ophthalmology and Visual Science, Chief of Vitreoretinal Service, and Shui-Chin Lee Professor of Ophthalmology and Visual Science at the University of Chicago Medicine. “I first worked with Harrow through IHEEZO, which helped improve the patient experience during intravitreal injection procedures, and later with TRIESENCE, an important treatment option for many patients. Throughout that time, their team has demonstrated an understanding of the clinical, operational, and economic realities retina specialists face every day. Adding BYOOVIZ to their portfolio is a natural extension of that experience. Having access to a trusted ranibizumab biosimilar from a company with experience supporting retina specialists makes BYOOVIZ a welcome addition to the treatment options available for patients.”

Physician Prescribing Information

Healthcare providers interested in prescribing BYOOVIZ (ranibizumab-nuna) for their patients can access prescribing information, patient support resources, and ordering details by visiting https://www.byooviz.com or by calling 1-833-4HARROW (442-7769).

BYOOVIZ® (ranibizumab-nuna) injection, for intravitreal use is a biosimilar to LUCENTIS (ranibizumab injection)

INDICATIONS AND USAGE
BYOOVIZ, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:

Neovascular (Wet) Age-Related Macular Degeneration (AMD)Macular Edema Following Retinal Vein Occlusion (RVO)Myopic Choroidal Neovascularization (mCNV)
IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Ocular or periocular infectionsHypersensitivity WARNINGS AND PRECATIONS

Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be monitored following the injectionIncreases in intraocular pressure (IOP) have been noted both pre- and post intravitreal injectionThere is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors
ADVERSE REACTIONS

The most common adverse reactions (reported more frequently in ranibizumab treated subjects than control subjects) are conjunctival hemorrhage, eye pain, vitreous floaters, and increased IOP
Please see full Prescribing information

OPUVIZ® (aflibercept-yszy) injection, for intravitreal use is a biosimilar to EYLEA (aflibercept)

INDICATIONS AND USAGE
OPUVIZ is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with:

Neovascular (Wet) Age-Related Macular Degeneration (AMD)Macular Edema Following Retinal Vein Occlusion (RVO)Diabetic Macular Edema (DME)Diabetic Retinopathy (DR) IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Ocular or periocular infectionsActive intraocular inflammationHypersensitivity
WARNINGS AND PRECATIONS

Endophthalmitis, retinal detachments, and retinal vasculitis with or without occlusion may occur following intravitreal injections. Patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment, or retinal vasculitis without delay and should be managed appropriately.Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection.There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors.
ADVERSE REACTIONS

The most common adverse reactions (≥5%) reported in patients receiving aflibercept were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.
Please see full Prescribing information

IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3%, for topical ophthalmic use

INDICATIONS AND USAGE

IHEEZO is an ester anesthetic indicated for ocular surface anesthesia.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

IHEEZO is contraindicated in patients with a history of hypersensitivity to any component of this preparation WARNINGS AND PRECATIONS

Not for Injection or Intraocular Administration.Corneal Injury Due to Insensitivity.Corneal OpacificationFor Administration by Healthcare Provider: IHEEZO is not intended for patient self-administration ADVERSE REACTIONS

Most common adverse reaction is mydriasis (approximately 25%)
Please see full Prescribing information

TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL

INDICATIONS AND USAGE
TRIESENCE® Suspension is indicated for:

Treatment of the following ophthalmic diseases: sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.Visualization during vitrectomy. IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

TRIESENCE® Suspension is contraindicated in patients with systemic fungal infections.TRIESENCE® Suspension is also contraindicated in patients with hypersensitivity to corticosteroids or any component of TRIESENCE® Suspension. Rare instances of anaphylactoid reactions have occurred in patients receiving corticosteroid therapy. WARNINGS AND PRECATIONS

TRIESENCE® is a suspension; it should not be administered intravenously.Ophthalmic effects: May include cataracts, infections, and glaucoma. Monitor intraocular pressure.Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing’s syndrome and hyperglycemia: Monitor patients for these conditions and taper doses gradually.Infections: Increased susceptibility to new infection and increased risk of exacerbation, dissemination, or reactivation of latent infection.Elevated blood pressure, salt and water retention, and hypokalemia: Monitor blood pressure and sodium, potassium serum levels.GI perforation: Increased risk in patients with certain GI disorders.Behavioral and mood disturbances: May include euphoria, insomnia, mood swings, personality changes, severe depression, and psychosis.Decreases in bone density: Monitor bone density in patients receiving long term corticosteroid therapy.Live or live attenuated vaccines: Do not administer to patients receiving immunosuppressive doses of corticosteroids.Negative effects on growth and development: Monitor pediatric patients on long-term corticosteroid therapy.Use in pregnancy: Fetal harm can occur with first trimester use.Weight gain: May cause increased appetite. ADVERSE REACTIONS

Based on a review of the available literature, the most commonly reported adverse events following ocular administration of triamcinolone acetonide were elevated intraocular pressure and cataract progression. These events have been reported to occur in 20-60% of patients.Less common reactions occurring in up to 2% of patients include: endophthalmitis (infectious and non-infectious), hypopyon, injection site reactions (described as blurring and transient discomfort), glaucoma, vitreous floaters, detachment of retinal pigment epithelium, optic disc vascular disorder, eye inflammation, conjunctival hemorrhage and visual acuity reduced. Cases of exophthalmos have also been reported. Please see full Prescribing information

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and diseases of the retina. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. As a wholly owned subsidiary of Samsung Epis Holdings, Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, endocrinology and neurology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the SEC. Such documents may be read free of charge on the SEC's web site at sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Contacts:

Mike Biega
Vice President of Investor Relations and Communications
[email protected]
617-913-8890

i Lucentis is a trademark of Genentech, Inc.
ii Eylea is a trademark of Regeneron Pharmaceuticals, Inc
iii Emergen Research, U.S. Anti-VEGF Market Size, Growth Outlook 2034
2026-07-01 12:09 1mo ago
2026-07-01 08:00 1mo ago
Starwood Capital Group Raises $10.2 Billion Opportunistic Real Estate Fund
STWD Starwood Property Trust
FMP Stock News
Original source text
Successful fundraising in challenging environment demonstrates enthusiasm for firm's core focus on real assets globally, extensive team experience and expertise across asset classes and geographies

, /PRNewswire/ -- Starwood Capital Group ("Starwood Capital"), a leading global private investment firm, today announced the successful final closing of its latest opportunistic real estate fund, Starwood Distressed Opportunity Fund XIII ("SOF XIII"), with capital commitments in excess of $10.2 billion. Together with existing commitments to Starwood Capital's other investment vehicles, the firm's assets under management now total approximately $130 billion.

SOF XIII will continue to focus on real assets globally, with the flexibility to shift between asset classes, geographies and positions in the capital stack. SOF XIII will primarily target transactions across the United States and Europe, with selective opportunities in Asia Pacific, and a focus on a strategic mix of residential, data center, industrial and hospitality assets.

SOF XIII was supported by more than 300 new and existing investors across approximately 20 countries, demonstrating broad enthusiasm for Starwood Capital's future and its extensive investment capabilities. This diverse and sophisticated investor base includes pensions, sovereign wealth funds, foundations, endowments, wealth managers, family offices and high net worth investors. In addition, Starwood Capital Group and related parties have committed $100 million to SOF XIII.

"We are very grateful for our investors' continued strong support. This is a testament to the strength of our team and the trust our LPs place in us," said Barry Sternlicht, Chairman and CEO of Starwood Capital. "We are excited about the opportunities we have already sourced for this fund and are proud of our track record of delivering results for our investors through market cycles. With our scale, resources and breadth of talent, we are well-positioned to execute on opportunities in this compelling environment for real estate."

"We could not be more proud of our brand, our strategy and our team's capabilities, and of the results we have consistently delivered for our investors," said Jonathan Pollack, President of Starwood Capital. "With a growing team of more than 350 investment professionals and an expanding global footprint, we have the talent, scale and conviction to continue delivering great performance. We are seeing strong tailwinds driven by slowing supply in traditional real estate asset classes and tremendous growth in technology and manufacturing – this is an exciting time to be investing in real estate."

Starwood Capital has already closed or committed to 20 transactions to date in SOF XIII, committing more than $3 billion of equity. This initial portfolio highlights the firm's breadth and global footprint, with significant investments in housing, industrial and data centers in each of the United States, Europe and Asia.

About Starwood Capital Group

Starwood Capital Group is a private investment firm with a core focus on real assets globally. Since its inception in 1991, Starwood Capital Group has raised over $95 billion of capital and currently has ~$130 billion of assets under management. Through a series of comingled opportunity funds and Starwood Real Estate Income Trust, Inc. (SREIT), a non-listed REIT, the Firm has invested in virtually every category of real estate on a global basis, opportunistically shifting asset classes, geographies and positions in the capital stack as it perceives risk/reward dynamics to be evolving.

Starwood Capital also manages Starwood Property Trust (NYSE: STWD), the largest commercial mortgage real estate investment trust in the United States, which has successfully deployed over $117 billion of capital since inception and manages a portfolio of over $31 billion across debt and equity investments. Alongside Starwood Property Trust, Starwood Capital manages over $6 billion in several private debt funds investing across the globe.

Starwood Capital's other affiliates include: Highmark Residential, a property management company; Starwood Digital Ventures, a platform dedicated to the firm's data center investment strategy; Starwood Hotels, a hotel brand management team; Essex Title, a title agent for one or more underwriters in issuing title policies and/or providing support services; and Starwood Oil & Gas, which seeks to capitalize on conventional and unconventional North American assets.

Additional information can be found at www.starwoodcapital.com, www.starwoodnav.reit, www.starwoodpropertytrust.com and www.starwoodhotels.com.

Media Contacts:

Dana Gorman / Mallory Griffin
H/Advisors – U.S.
[email protected] / [email protected]
212.371.5999

SOURCE Starwood Capital Group
2026-07-01 12:05 1mo ago
2026-07-01 05:45 1mo ago
SpaceX Has Tumbled 27% From Its Recent Peak. Time to Buy the Dip?
SPCX SpaceX
FMP Stock News
Original source text
Space Exploration Technologies (SPCX +4.15%), or SpaceX, roared out of the gate following its initial public offering on June 12, reaching an intraday high of roughly $225.64 per share on June 16. As of this writing, the company's share price is down roughly 27% from that high point.

SpaceX has leading positions in rocket-launching technologies and satellite internet and mobile services, and it appears to be in the early stages of building a top artificial intelligence (AI) services business. Should investors buy the stock following its substantial valuation pullback?

Image source: Getty Images.

Does SpaceX stock offer compelling value right now? SpaceX still has a market capitalization of roughly $2.16 trillion. At that valuation, the company trades at approximately 115 times last year's $18.7 billion in revenue. SpaceX posted annual sales growth of 33% in 2025, and there's a good chance the business is actually poised for meaningful acceleration when it comes to revenue growth this year, thanks to new AI processing contracts, expansion for the adoption of Starlink services and product portfolios, and continued growth for its rocket-launching services.

But there's a good chance that SpaceX's net loss will also expand significantly from last year. The business posted a net loss of roughly $4.9 billion last year, with its AI business accounting for the vast majority of those losses. Notably, the AI unit is the focal point of the company's growth ambitions -- and massive infrastructure spending this year should lead to a large increase in the business's net loss.

Today's Change

(

4.15

%) $

6.82

Current Price

$

171.01

Even though SpaceX has seen a big valuation pullback following its post-IPO high, the company still trades at an enormously growth-dependent valuation. The likelihood that the company's net loss will jump significantly this year presents a big risk factor, and that isn't the only potential valuation headwind on the horizon. If investors become less willing to assign big valuation premiums to AI processing and space tech stocks, SpaceX stock could continue to tumble.

With that in mind, I think that investors who want to own a piece of the company will be best served by waiting for a better entry point.

Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
2026-07-01 12:05 1mo ago
2026-07-01 06:11 1mo ago
SpaceX Stock Now Has a Price to Sales Ratio Over 115x. Is It Worth Buying Anyway?
SPCX SpaceX
FMP Stock News
Original source text
Even after cooling off from its post-IPO rally, Space Exploration Technologies (SPCX +4.15%), better known as SpaceX, has a market cap of $2.25 trillion and is one of the most valuable companies in the world. Based on its revenue of about $19.3 billion over the past four quarters, SpaceX has a price-to-sales ratio of about 116.

Let's be clear. That's an incredibly high multiple. Some of the most rapidly growing AI infrastructure stocks trade for P/S multiples in the 40-50 range. The average S&P 500 company trades for about 3x sales. But there's more to the story. The price-to-sales ratio of 116 is a backward-looking metric. The more important thing to consider is whether SpaceX's revenue in 2027, 2028, and beyond will justify it.

Image source: Getty Images.

What will SpaceX's revenue be? SpaceX's revenue is a unique situation because its trailing 12-month revenue and what investors should expect going forward are two different things.

The biggest reason is SpaceX's recent AI compute deals. Between three separate deals with Anthropic, Alphabet's (GOOGL +1.09%)(GOOG +0.67%) Google, and Reflection AI, SpaceX will be receiving about $2.32 billion per month in AI compute revenue once all three deals are in effect (starting in October). That's $27.8 billion in annual revenue from these three deals alone.

Today's Change

(

4.15

%) $

6.82

Current Price

$

171.01

Beyond the AI compute deals, it's important to point out that SpaceX's Starlink satellite internet service grew revenue by 50% year-over-year in 2025 and has barely scratched the surface of its addressable market opportunity. Plus, once SpaceX's much larger Starship rocket begins commercial flights, it could be a big revenue growth driver.

SpaceX's revenue will almost certainly grow substantially in the second half of 2026 and beyond. Looking ahead to 2027, there's a solid base case to be made that SpaceX will get about $22-24 billion in revenue from Starlink, $30 billion from xAI (including the AI compute deals, the X social media platform, and Grok, and about $6 billion from the rocket launch business, for a total of about $59 billion. This would give SpaceX a much lower P/S multiple of 38 based on its current valuation, and revenue could potentially be even higher if the company gets additional AI compute deals.

The biggest caveat is that even a P/S of 38 is expensive, and we have no idea whether SpaceX will be profitable in 2027. There will likely still be a lot of future revenue and earnings growth priced into the stock. The bottom line is that (assuming its AI compute deals produce the three years of revenue that is expected) SpaceX's stock is effectively much less expensive than its 116x P/S multiple implies. But it's still an expensive business. Approach it with that in mind.

Matt Frankel, CFP® has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet. The Motley Fool has a disclosure policy.
2026-07-01 12:05 1mo ago
2026-07-01 08:00 1mo ago
Here's a Massive Reason You Should Buy SpaceX Before July 7th
SPCX SpaceX
FMP Stock News
Original source text
© 24/7 Wall St / Getty Images

The thesis is straightforward: SpaceX (NASDAQ:SPCX) gets added to the Nasdaq-100 on July 7, and every index fund, ETF and benchmark-tracking pension on the planet has to buy it whether they like the valuation or not. That is mechanical demand against a float that has been public for 11 trading days, and it is the cleanest forced-flow catalyst the market has seen in years.

The Catalyst Is Already Priced In, but Not Enough Nasdaq announced the inclusion after Friday’s close, calling it one of the quickest ever additions to the high-profile index following last month’s rule change. Prediction markets have caught on. Polymarket is currently pricing a 92% probability that SPCX closes the week of June 29 above $145, with the single most-favored outcome being a close above $175 at 31% implied probability. The stock is already up 6% over the past week heading into the trigger date. Funds front-running the rebalance are buying now, not on July 7.

The Revenue Story Has Quietly Doubled The bear case rests on a stale revenue number. SpaceX did $18.7 billion in 2025 revenue, up 33% year over year, with a GAAP loss. That was the pre-xAI company. Post-merger, the AI segment has signed contracts totaling $27.8 billion in annual revenue with Anthropic, Alphabet and Reflection AI.

The Anthropic deal alone pays $1.25 billion per month for roughly 300 megawatts of Colossus compute. The Google deal adds $920 million per month for about 110,000 GPUs through 2029. Stack that on Q1 2026 sales of $4.7 billion, and the company is tracking to $38.6 billion in revenue this year. That is a hyperscaler growth profile that did not exist six weeks ago.

Wall Street Targets Confirm The Upside Current price sits around $170. The consensus analyst target is $187.80, implying 11% upside before the index buying even begins. Sentiment has moved with the setup, with the composite score climbing +14.95 over the past seven days.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and SpaceX didn't make the cut. Grab the names FREE today.

Defiance ETFs CIO Sylvia Jablonski put it bluntly, arguing “investors are underestimating SpaceX by viewing it solely as an aerospace company” and pointing to Starlink and AI connectivity as the underappreciated legs of the story.

The Valuation Risk, Dismissed The pushback writes itself: The stock trades at 112 times trailing sales, which is the wrong number to anchor on. On forward revenue of $38.6 billion, the multiple compresses to roughly 54 times sales, and that figure shrinks every quarter the hyperscaler deals scale. Palantir trades at 37 times forward sales with materially slower growth. SpaceX is growing the top line at a rate that closes that gap inside of two reporting cycles.

The catalyst is dated, the buyers are forced, and the revenue trajectory has already re-rated. Investors positioning ahead of July 7 are making a straightforward call.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and SpaceX didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.
2026-07-01 12:05 1mo ago
2026-07-01 06:20 1mo ago
‘Big Short' Michael Burry just bet against this Elon Musk company
TSLA Tesla
FMP Stock News
Original source text
While shareholders might have welcomed Tesla (NASDAQ: TSLA) stock’s weekly 11% climb to $420.60, the climb is merely a temporary move ahead of a continued decline in the long run, at least judging by ‘Big Short’ Michael Burry’s latest market bet.

Specifically, the legendary short trader wrote on June 30 that TSLA equity’s rally finally enabled him to make a bearish trade against Elon Musk’s older public company while it was at $416.22:

And finally I shorted Tesla (TSLA) at 416.22. Happy it jumped back to this level.

Notably, Burry did not disclose the scale of his bet nor any other details in his premium Substack post titled ‘Trading Post June 30th, 2026.’ 

It did, however, reveal that the famous short-seller might be uncertain regarding the depth of Tesla’s incoming correction as he was, apparently, unwilling to take a position near the June 26 closing price of $379.71, or even June 29’s $411.84.

Tesla stock price one-week chart. Source: Google 2026 Tesla stock price performance Meanwhile, investor confidence in TSLA shares appears to be, at best, shaken in recent months. Indeed, after the electric vehicle (EV) maker’s equity soared toward $500 in late 2025, exceeding both the 2024 and 2021 highs, subsequent trading has been mostly bearish.

Even with the latest 11% upward move, Tesla stock remains 3.99% in the red year-to-date (YTD), and the July 30 pre-market might already be proving Burry’s assessment correct, considering that, by press time, the company is 0.67% down to $417.79.

So far, the deteriorating sentiment is most likely the result of dwindling EV sales and the perpetually shifting timetable for the ‘Robotaxi’ and FSD – autonomous driving system – rollout, but is also likely linked to the capital-hungry and recent SpaceX (NASDAQ: SPCX) initial public offering (IPO).

Michael Burry shorted these stocks at the end of Q2, 2026 Elsewhere, Michael Burry revealed that Tesla is far from the only company he considers overvalued at the end of the second quarter (Q2) of 2026. 

In the June 30 update on Substack, he disclosed taking a short position against Caterpillar (NYSE: CAT) at $1,060.98, Applied Materials (NASDAQ: AMAT) at $729.40, and the popular iShares Semiconductor ETF (SOXX) at $642.80.

Lastly, Burry appears to have doubled down on his bet against Nvidia (NASDAQ: NVDA) as he disclosed a bearish position at $198.09 in the June 30 trade update.

Featured image via Shutterstock

Best Crypto Exchange for Intermediate Traders and Investors

Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

Copy top-performing traders in real time, automatically.

eToro USA is registered with FINRA for securities trading.

30+ million Users worldwide

eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more.

Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!
2026-07-01 12:05 1mo ago
2026-07-01 07:17 1mo ago
Tesla Deliveries Should Show a Second Straight Quarter of Growth
TSLA Tesla
FMP Stock News
Original source text
In this article

TSLA

SPX

DJIA

Coming into Wednesday trading, Tesla stock was down about 6% this year and up about 32% over the past 12 months. (Loic Venance / AFP via Getty Images)

Tesla is set to report deliveries over a period that included a war, soaring oil prices, and the ongoing effects of U.S. electric-vehicle policy changes.
2026-07-01 12:05 1mo ago
2026-07-01 07:30 1mo ago
Tesla deliveries are set to rise — no thanks to the U.S.
TSLA Tesla
FMP Stock News
Original source text
HomeIndustriesAutomobilesEurope should be a source of strength when Tesla posts its second-quarter delivery numbers later this weekJuly 1, 2026, 7:30 a.m. ET

Tesla is set to report second-quarter sales on Thursday, with Wall Street forecasting limited growth as the U.S. electric-vehicle market struggles to show a meaningful bounce.

The company is expected to have sold between 401,000 and 406,024 vehicles in the just-completed second quarter, implying growth of up to 5.7% from a year earlier, according to analysts. That would also reflect an improvement from earlier in the year, when Tesla TSLA reported disappointing March quarter sales.
2026-07-01 12:05 1mo ago
2026-07-01 07:11 1mo ago
Swedish court says Google is to pay $1.5 billion to Klarna in antitrust damages
GOOGL Alphabet
FMP Stock News
Original source text
The Google logo is pictured at the entrance to the Google offices in London, Britain January 18, 2019. REUTERS/Hannah McKay/File Photo/File Photo Purchase Licensing Rights, opens new tab

SummaryCompaniestheSTOCKHOLM, July 1 (Reuters) - A Swedish ‌court said on Wednesday Alphabet's Google (GOOGL.O), opens new tab is to pay ​the equivalent of around ​14.3 billion Swedish crowns ($1.5 billion) ⁠in antitrust damages to ​Klarna's (KLAR.N), opens new tab price comparison company PriceRunner.

"PriceRunner ​is considered to have suffered damage as a result of ​Google having illegally favoured ​its price comparison service for many ‌years," ⁠the Stockholm Patent and Market Court said in a statement.

The Reuters Daily Briefing newsletter provides all the news you need to start your day. Sign up here.

PriceRunner in 2022 sued ​Google for ​around €2.1 ⁠billion ($2.4 billion) at the court, saying the ​company breached antitrust ​laws ⁠by manipulating search results in favour of its own ⁠comparison ​shopping services.

($1 = 9.7291 ​Swedish crowns)

($1 = 0.8775 euros)

Reporting by Anna ​Ringstrom, editing by Essi Lehto

Our Standards: The Thomson Reuters Trust Principles., opens new tab
2026-07-01 12:05 1mo ago
2026-07-01 07:27 1mo ago
Google Parent Alphabet is the 'Best Chart': Strategas Chief Chartist Says Stock Tells a 'Different Story' As Rivals Look 'Ugly'
GOOGL Alphabet
FMP Stock News
Original source text
According to Strategas chief chartist Todd Sohn, the search giant boasts the “best chart” in big tech right now, carving out a “different story” as its closest sector rivals start to look “ugly” on a technical basis.

The Big Tech DivergenceAppearing on The Real Eisman Playbook podcast with famed investor Steve Eisman, Sohn highlighted a striking technical divergence ripping through the technology sector. While the broader market cap-weighted indices continue to float near highs, under the hood, foundational tech icons are showing severe signs of exhaustion.

“If you just compared on one screen Google, Alphabet… Meta, Microsoft, you’d have Google would be the contrast there,” Sohn observed, noting that the company’s chart looks exceptionally strong.

Sohn labeled Microsoft’s recent price action a “red flag,” describing it as “ugly compared to again a market that’s making a new high.”

The AI Power ConnectionEisman chimed in on the connection, noting that Alphabet and GE Vernova are likely “in cahoots together, powering… the AI of Google.”

While Sohn warned that Alphabet did get “very extended” and “super overbought” recently—likening it to a runner who is “exhausted” after running a four-minute mile—he remains highly constructive on the name.

For investors looking for an entry point, Sohn suggests that any near-term profit-taking will ultimately present an attractive opportunity, concluding that the stock “will likely be buyable.”

GOOG’s Technical ChartAs of the June 30 close at $353.33 apiece, GOOG’s technical profile presents a mixed, transitional picture as the stock cools off from its aggressive May highs. Here is a breakdown of the current technical indicators, according to Benzinga Pro.

How Has GOOG Performed In 2026?GOOG shares have advanced by 12.60% year-to-date, down 6.14% over the last month, and up 99.14% over the year. The stock closed 0.58% higher at $353.33 apiece on Tuesday, and it was 0.37% lower in premarket on Wednesday.

Benzinga’s Edge Stock Rankings indicate that GOOG maintains a weak price trend in the short term but a strong trend in the long and medium terms, with a poor value score.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Image via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.
2026-07-01 12:05 1mo ago
2026-07-01 07:00 1mo ago
If a Stock Market Crash Is Coming, History Says Investors Who Do This 1 Thing Will Win Out
AMZN Amazon
FMP Stock News
Original source text
The market has been wobbly lately, with the S&P 500 (^GSPC +0.79%) and Nasdaq Composite (^IXIC +1.52%) dipping by nearly 3% and 6%, respectively, over the past month.

Some stock market indicators are also sounding the alarm. The S&P 500 Shiller CAPE Ratio, which measures whether the index is over- or undervalued, is reaching heights not seen since the dot-com bubble burst. Back then, the ratio reached a record high of around 44. As of this writing, it's just over 41, the second highest point in history.

The Buffett indicator, named after Warren Buffett, is also at record highs. This metric measures the relationship between the total value of U.S. stocks and GDP, and according to Buffett himself, investors are "playing with fire" when it nears 200%. Currently, this metric sits at around 234%.

To be clear, this doesn't necessarily mean that a market crash is imminent or that we're in a bubble that's about to pop. The market is incredibly complex, and trying to predict what will happen in the near term can be costly. Fortunately, there's one move that history says never steers investors wrong.

Image source: Getty Images.

History says this is the best move investors can make While it's impossible to say when the next downturn will begin, it's bound to happen eventually. And when it does, investors who own a healthy portfolio of quality stocks will win out.

Many stocks have experienced unprecedented growth in recent years, but a soaring stock price doesn't necessarily mean the underlying company is healthy. Some stocks are fueled by hype and speculation, so even if they appear to be thriving on paper, they could be incredibly overvalued and due for a pullback soon.

During the dot-com bubble in the early 2000s, for example, hundreds of tech companies crashed and burned. Although many of these high-profile stocks had soared in valuation in the years leading up to the bursting bubble, factors such as unsustainable business models and poor finances made it impossible for them to survive the bear market that followed.

^SPX data by YCharts

Not all tech companies failed during that time, though. Those with solid fundamentals were resilient enough to weather the collapse of the tech sector, and the S&P 500 itself has delivered total returns of more than 700% since 2000.

Right now is a particularly smart time to comb through your portfolio and ensure you're investing only in stocks whose valuations align with their underlying fundamentals. With the market still near record highs, now could be a good moment to sell any stocks that are no longer healthy investments.

A long-term outlook is more important than ever If a bear market or recession is coming, even strong stocks can take a beating. Investors who hold their stocks for at least a few years, however, will be in the best position for substantial growth.

During the dot-com bear market, for instance, Amazon (AMZN 0.68%) lost nearly 95% its value. Many investors would have been tempted to jump ship during that time, but those who stayed the course would have doubled their money in a little over a decade. Between 1999 and today, Amazon has earned total returns of more than 4,000%.

AMZN Total Return Level data by YCharts

In the short term, the market can be brutal. But if history proves anything, it's that strong companies have the best shot at surviving volatility and delivering positive total returns over time.

When you're choosing stocks, look for key metrics suggesting a fundamentally sound company. Focusing on factors such as a company's business model, profitability, leadership team, and industry health can make it easier to determine whether a stock will survive a downturn.

No matter what's coming for the market, history says that investing in quality companies and holding them for the long haul will set you up for success.
2026-07-01 12:04 1mo ago
2026-07-01 06:10 1mo ago
MSFT Lawsuit Notification: Microsoft Investors Bring Securities Class Action Following Functionality Issues – Contact BFA Law by August 11 Deadline
MSFT Microsoft
FMP Stock News
Original source text
NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Microsoft Corporation (NASDAQ:MSFT) and certain of the Company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

If you invested in Microsoft, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/microsoft-class-action-lawsuit.

Key Details of the Microsoft ($MSFT) Class Action:

Lead Plaintiff Deadline: August 11, 2026Alleged Misconduct: Securities fraud alleging that Microsoft misled investors regarding its Azure cloud computing platform and AI chatbot CopilotStock Drop: January 28, 2026 – 10% Stock DropCourt: U.S. District Court for the Western District of WashingtonAction: Contact BFA Law to discuss your rights Investors have until August 11, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Microsoft common stock. The class action is pending in the U.S. District Court for the Western District of Washington. It is captioned City of St. Clair Shores Police and Fire Retirement System, et al., No. 26-cv-02071.

Why is Microsoft Being Sued for Securities Fraud?

Microsoft is a multinational technology company that develops software, cloud services, and devices. In recent years, Microsoft’s cloud computing platform named Azure has been Microsoft’s main growth driver. A key reason for Azure’s recent growth is Microsoft’s multi-billion-dollar investment into AI, including the development of its own generative AI chatbot named Copilot.

According to the complaint, during the relevant period, Microsoft consistently touted Copilot’s best-in-class capabilities, which purportedly drove widespread and growing user adoption. Copilot’s apparent success allowed Microsoft to report surging Azure-related revenue.

As alleged, in truth, Copilot suffered from severe functionality issues that caused user adoption to decline and put Microsoft’s Azure revenue at risk.

Why did Microsoft’s Stock Drop?

On January 28, 2026, Microsoft announced disappointing 2Q 2026 financial results and that Azure growth had slowed suddenly. Microsoft also allegedly revealed for the first time that the number of Microsoft 365 Copilot premium customers totaled only 15 million, materially below analyst estimates.

This news caused the price of Microsoft common stock to decline $48.13 per share, or 10%, from $481.63 per share on January 28, 2026, to $433.50 per share on January 29, 2026.

Additionally, on February 3, 2026, The Wall Street Journal reported in an article titled “Microsoft’s Pivotal AI Product Is Running Into Big Problems” that severe challenges and functionality issues had plagued Copilot, causing the application to lose market share. Specifically, The Wall Street Journal reported that “[c]onfusing brand positioning and interoperability problems have frustrated users.”

Click here for more information: https://www.bfalaw.com/cases/microsoft-class-action-lawsuit.

What Can You Do?

If you invested in Microsoft, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/microsoft-class-action-lawsuit

Or contact:
Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/microsoft-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.
2026-07-01 12:03 1mo ago
2026-07-01 06:06 1mo ago
Top Wall Street Forecasters Revamp Citigroup Expectations Ahead Of Q2 Earnings
C Citigroup
FMP Stock News
Original source text
Citigroup Inc. (NYSE:C) will release earnings for its second quarter before the opening bell on Tuesday, July 14.

Analysts expect the New York-based company to report quarterly earnings of $2.64 per share, up from $2.04 per share in the year-ago period. The consensus estimate for Citigroup’s quarterly revenue is $23.37 billion. It reported $21.67 billion last year, according to Benzinga Pro.

On June 4, Citigroup announced $2.75 billion redemption of 1.462% fixed rate/floating rate notes due 2027 and $400 million redemption of floating rate notes due 2027.

Shares of Citigroup fell 1.8% to close at $139.96 on Tuesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

Considering buying C stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.
2026-07-01 12:03 1mo ago
2026-07-01 02:03 1mo ago
Nike turnaround tested but 'this is the bottom', says analyst
NKE Nike
FMP Stock News
Original source text
Nike Inc (NYSE:NKE) shares fell in after-hours trading as the latest results showed the sportswear giant is still struggling to turn better products into stronger sales.

Fourth-quarter revenue fell 1% to $11 billion, or 4% on a currency-neutral basis, with weakness in Greater China and Europe partly offset by growth in North America. It was the lowest sales total since early 2022.

Wholesale revenue rose 4% to $6.6 billion, suggesting Nike is making some progress in repairing relationships with retail partners. But Nike Direct fell 7% to $4.1 billion, hit by a 12% drop in digital sales and a 7% decline in Nike-owned stores. Converse revenue fell 32% to $244 million.

Net income came in at $1.07 billion, helped by a $986 million tariff-related refund. Gross margin rose to 49.2% from 40.3%, although it would have been roughly flat without the refund.

Full-year profit was down 3% at $3.1 billion. 

The bigger issue was guidance, as Nike expects revenue to fall by low- to mid-single digits over the next two quarters, while earnings are expected to be "flattish".

Chief financial officer Matthew Friend said: "The environment around us continues to be volatile."

Nike is in the middle of a turnaround under chief executive Elliott Hill, who is shifting back towards retail partners after losing shelf space to newer rivals such as On, Hoka, Alo and local sportswear brands in China. 

Analysts at Jefferies said: "This is the bottom", pointing "kernels" of encouragement such as better inventory control and growth in running and football.

"The China cleanup is progressing while the performance biz continues to scale. Sportswear and Jordan streetwear remain the overhang and will take time, but the core is stabilizing."

Running is "the clearest proof point", up by double digits for the fifth straight quarter helped by footwear share gains in North America and Western Europe, with football also up across georaphies, basketball "building", and training, tennis and golf "all chipped in".

Victoria Scholar at interactive investor said Nike had "firmly fallen out of fashion", with competition and weak consumer spending still weighing on the brand.

She said the results looked "respectable" at first glance, but said investors looked past that as guidance was "suggesteng little near-term improvement" and competition still building.

"Nike has been trying to leverage the World Cup to support its turnaround plans and build momentum through advertising and social media, however there’s a long way to go for Nike to revitalise its former dominance and trend chasing shoppers are notoriously fickle."

Shares in Nike were down 3.9% to $39.46 in pre-market trading on Wednesday, down by more than 35% so far this year.
2026-07-01 12:03 1mo ago
2026-07-01 05:29 1mo ago
JD Sports falls on read-across from Nike warning
NKE Nike
FMP Stock News
Original source text
JD Sports Fashion PLC (LSE:JD., OTC:JDSPY) shares fell on Wednesday after results from major partner Nike Inc (NYSE:NKE) pointed to weaker sales ahead and continued pressure on consumer demand.

The sports fashion retailer was down 2.3% at 82.78p, as investors read across from Nike’s fourth-quarter numbers overnight.

Nike reported quarterly net income of $1.07 billion, helped by a $986 million tariff-related refund. Without that boost, the trainer maker’s underlying performance remained weak.

Revenue was flat at $11 billion, the lowest quarterly figure since February 2022. China sales fell 17% on a currency-neutral basis, while its sportswear business declined by double digits globally.

Nike’s gross margin rose to 49.2% from 40.3%, but the company said margins would have been roughly flat without the tariff refund.

The bigger concern was guidance, as the Oregon sportswear giant maintained its forecast for flat earnings over the next two quarters, but said revenue would fall by low- to mid-single digits.

It blamed tariff risk, disruption in the Middle East and weak consumer sentiment linked to high oil prices. "The environment around us continues to be volatile," chief financial officer Matthew Friend said.

Analysts at Peel Hunt said: "In terms of read-across to JD, this is clearly not positive,".

The broker added: “We do not believe that is at significant risk, but consensus EBITDA of £786 million (PHe: £785 million), which is in the bottom half of the company's guided range, appears to be the right ballpark.”

"However, the risk is probably skewed slightly to the downside, absent a dramatic improvement in consumer confidence."

The broker reiterated its view that JD "remains, however, a very cheap stock, in our view, given its global position as the partner of choice for brands and consumers".
2026-07-01 12:03 1mo ago
2026-07-01 06:24 1mo ago
Nike turnaround tested by but analyst says 'this is the bottom'
NKE Nike
FMP Stock News
Original source text
Nike Inc (NYSE:NKE) shares fell in after-hours trading as the latest results showed the sportswear giant is still struggling to turn better products into stronger sales.

Fourth-quarter revenue fell 1% to $11 billion, or 4% on a currency-neutral basis, with weakness in Greater China and Europe partly offset by growth in North America. It was the lowest sales total since early 2022.

Wholesale revenue rose 4% to $6.6 billion, suggesting Nike is making some progress in repairing relationships with retail partners. But Nike Direct fell 7% to $4.1 billion, hit by a 12% drop in digital sales and a 7% decline in Nike-owned stores. Converse revenue fell 32% to $244 million.

Net income came in at $1.07 billion, helped by a $986 million tariff-related refund. Gross margin rose to 49.2% from 40.3%, although it would have been roughly flat without the refund.

Full-year profit was down 3% at $3.1 billion. 

The bigger issue was guidance, as Nike expects revenue to fall by low- to mid-single digits over the next two quarters, while earnings are expected to be "flattish".

Chief financial officer Matthew Friend said: "The environment around us continues to be volatile."

Nike is in the middle of a turnaround under chief executive Elliott Hill, who is shifting back towards retail partners after losing shelf space to newer rivals such as On, Hoka, Alo and local sportswear brands in China. 

Analysts at Jefferies said: "This is the bottom", pointing "kernels" of encouragement such as better inventory control and growth in running and football.

"The China cleanup is progressing while the performance biz continues to scale. Sportswear and Jordan streetwear remain the overhang and will take time, but the core is stabilizing."

Running is "the clearest proof point", up by double digits for the fifth straight quarter helped by footwear share gains in North America and Western Europe, with football also up across georaphies, basketball "building", and training, tennis and golf "all chipped in".

Victoria Scholar at interactive investor said Nike had "firmly fallen out of fashion", with competition and weak consumer spending still weighing on the brand.

She said the results looked "respectable" at first glance, but said investors looked past that as guidance was "suggesteng little near-term improvement" and competition still building.

"Nike has been trying to leverage the World Cup to support its turnaround plans and build momentum through advertising and social media, however there’s a long way to go for Nike to revitalise its former dominance and trend chasing shoppers are notoriously fickle."

Shares in Nike were down 3.9% to $39.46 in pre-market trading on Wednesday, down by more than 35% so far this year.
2026-07-01 12:03 1mo ago
2026-07-01 06:24 1mo ago
Nike stock: why did a rare earnings beat fail to lift shares?
NKE Nike
FMP Stock News
Original source text
Nike shares fell 4% in premarket trading on Wednesday after the sportswear giant's latest quarterly results failed to convince investors that its turnaround under Chief Executive Officer Elliott Hill is gathering pace.

Although Nike topped Wall Street expectations for both earnings and revenue, a cautious outlook for the coming quarters, persistent weakness in China and continued uncertainty around consumer demand overshadowed the better-than-expected performance.

The company's results also weighed on European sportswear stocks, with Adidas and Puma both falling more than 1% in early trading.

Nike shares have already declined around 35% this year as investors grow increasingly concerned about the pace of the company's recovery amid rising competition and shifting consumer preferences.

Nike reported fiscal fourth-quarter earnings of 20 cents a share, excluding a 52-cent benefit related to the expected recovery of import tariffs.

Revenue declined 1.1% from a year earlier to $11 billion.

Analysts polled by LSEG had expected earnings of 12 cents per share on revenue of $10.9 billion.

Despite the earnings beat, investors focused on management's guidance that sales are expected to continue declining through the first half of fiscal 2027 as the company navigates tariff pressures, geopolitical uncertainty and cautious consumer spending.

Nike now expects revenue to decline by low- to mid-single digits during the period from March through November, compared with its earlier forecast for a low-single-digit decline.

The company also continues to expect earnings to remain largely flat over the same period.

"We are not expecting the environment to improve meaningfully over the next six months," Chief Financial Officer Matthew Friend said during the earnings call, citing evolving tariff policies, conflict in the Middle East and oil prices as factors that could pressure both costs and consumer demand.

Given the uncertain backdrop, Nike plans to tighten inventory and reduce orders, a strategy management believes will support margins but weigh on near-term revenue.

Despite the muted outlook, some analysts said Nike's renewed focus on sports is beginning to deliver encouraging signs.

Jefferies analysts said the company's fiscal fourth-quarter results were better than feared.

"Nike's emphasis on its sports business is showing early signs of paying off, though performance in China remains a drag on the company," the brokerage wrote.

According to Jefferies, Elliott Hill's "sport offense" strategy has helped return Nike's wholesale business to growth, validating the company's renewed emphasis on performance categories.

However, analysts said continued weakness in Nike's direct-to-consumer business, including its retail stores and digital platform, remains a significant challenge.

Nike has spent the past two years rebuilding relationships with wholesale partners while attempting to reduce excess lifestyle inventory that had weighed on sales and margins.

The company also pointed to early progress in several areas, including stronger World Cup marketing campaigns, faster product launches and improving football demand after a slowdown in April.

Management forecast a slightly positive gross margin during the first quarter and said more than a dozen new footwear styles are scheduled for launch as part of the company's product refresh.

CEO Elliott Hill acknowledged that rebuilding consumer demand will take time.

"We know we're not living up to our full potential," he said.

China remains one of Nike's biggest obstacles.

Revenue in Greater China, which accounts for roughly 15% of Nike's annual sales and is its third-largest market after North America and Europe, the Middle East and Africa, continued to post double-digit declines during the quarter.

Outgoing finance chief Matthew Friend said the company expects China to remain under pressure as Nike works with retail partners to clear excess inventory.

Some analysts said the restructuring effort is beginning to show signs of progress but warned that meaningful sales growth is unlikely until the inventory reset is complete.

Nike is pursuing a more premium, sports-focused strategy in China, although analysts expect the benefits of that approach to emerge gradually rather than immediately.

Hill said the company expects newly launched footwear products to contribute more meaningfully to growth during 2027 as the broader product pipeline gains traction.

Analysts remain divided over how quickly Nike can regain lost market share.

Bernstein said the company's decision to prioritise marketplace health over short-term revenue growth is strategically sound but likely to delay any meaningful earnings recovery.

"Revenue declines through H1 mean no earnings growth until at least H2'27 as Nike prioritizes marketplace health over near-term sales — a good decision for the company but not for rapid recovery of the stock," Bernstein analysts said.

Nike has struggled to regain momentum after losing customers to newer athletic brands while also dealing with softer consumer demand globally.

In March, management acknowledged that efforts to revive growth were taking longer than expected despite improving trends in North America, particularly in running and football footwear.

Some analysts, however, remain unconvinced that Nike's latest product launches have resonated strongly enough with consumers.

The company's digital business has also remained under pressure as Nike attempts to reposition the platform around higher-priced products rather than relying on discounting.

The prolonged decline in Nike's share price has also prompted speculation that the stock could eventually lose its place in the Dow Jones Industrial Average.

Wall Street has become increasingly cautious in recent weeks.

KeyBanc Capital Markets downgraded the stock last week, saying investors may have to wait until Nike's investor day later this year before gaining greater confidence in the company's long-term turnaround strategy.

Even after Wednesday's decline, Nike trades at a forward price-to-earnings multiple of about 21.95, above Adidas' multiple of 16.81, according to LSEG data, suggesting investors continue to price in a recovery that has yet to fully materialise.
2026-07-01 12:03 1mo ago
2026-07-01 07:31 1mo ago
Stocks close out Q2, Nike earnings, egg prices and more in Morning Squawk
NKE Nike
FMP Stock News
Original source text
This is CNBC's Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.

Happy Wednesday. While consumer sentiment is near record lows, at least one group appears to be feeling better about their jobs: shift workers.

Stock futures are mixed this morning after a winning day on Wall Street.

Here are five key things investors need to know to start the trading day:

1. Heat wave2. Red cliffNike reported stronger-than-expected results for the fiscal fourth quarter. But the athletic retailer posted a 12% sales drop in the closely watched China market, leading shares down 3% in extended trading.

Total revenue ticked down 1% from the same quarter a year prior. While revenue for North America rose 3%, it still came up short of Wall Street's consensus forecast.

On the other hand, the Oregon-based company said its gross margin grew by nearly 9% in the quarter. As CNBC's Laya Neelakandan notes, that was driven in part by an expected tariff refund after the Supreme Court struck down many of President Donald Trump's levies.

3. Live from PortugalIn an interview with CNBC's Sara Eisen yesterday, Cleveland Federal Reserve President Beth Hammack called the demand for artificial intelligence infrastructure "insatiable." And she warned that it could drive up inflation.

Hammack said during the European Central Bank Conference in Sintra, Portugal, that inflation has been "too high" for the past five years. As a result, she said the Fed may need to raise interest rates.

Don't miss Eisen's panel with Fed Chair Kevin Warsh, European Central Bank President Christine Lagarde, Bank of England Governor Andrew Bailey and Bank of Canada Governor Tiff Macklem at 9 a.m. ET. Watch live on CNBC and CNBC+.

4. Looking forwardAmazon announced yesterday that it's investing $1 billion into a new Forward Deployed Engineering team for the Web Services business. As CNBC's Ashley Capoot notes, Amazon is considered the first hyperscaler to unveil this type of group.

A forward deployed engineer is embeded within a business with the goal of accelerating technical transformation and dispatching AI. While Palantir coined the FDE title more than a decade ago, the job got increasingly popular among software vendors aiming to bring their talent into client facilities.

Meanwhile, Amazon founder Jeff Bezos' Blue Origin said it would not rebuild a launchpad where one of its rockets exploded. Instead, the startup will focus on a redesign with the goal of a return to flying this year.

5. Over easyMajor egg producers settled a price inflation probe with the Justice Department and several state attorneys general. As part of the deal, the companies agreed to donate around 53 million eggs to food banks and related nonprofits.

The DOJ and states alleged that Cal-Maine Foods, Versova and Hickman's Egg Ranch "illegally coordinated" for almost three years to raise a daily price index for the food. The proposed settlements would prevent the companies from "coordinated" price manipulation in the future by adding antitrust compliance programs and compliance officers. The settlements still require federal judge approval.

The Daily DividendMembers of Congress on both sides of the aisle are taking a look at the role of private equity in youth sports. Here's what Rep. Kevin Kiley, chair of the House Early Childhood, Elementary and Secondary Education subcommittee, said during a hearing on the matter yesterday:

The simple reality is that too many children are being priced out. It’s not that they lack talent or determination; it’s that their families simply cannot afford the rising costs.

Rep. Kevin Kiley

Chair of the House Early Childhood, Elementary and Secondary Education subcommittee

— CNBC's Sean Conlon, Kif Leswing, Samantha Subin, Sam Meredith, Laya Neelakandan, Jeff Cox, Ashley Capoot, Annie Palmer, Greg Iacurci and Garrett Downs contributed to this report.

Luke Fountain assisted in the production of this newsletter. Melodie Warner edited this edition.
2026-07-01 12:03 1mo ago
2026-07-01 05:37 1mo ago
Which "Magnificent Seven" Stock Is Reporting the Fastest Revenue and Profit Growth?
NVDA Nvidia
FMP Stock News
Original source text
When discussing the market's performance over the past few years, it's impossible not to mention the "Magnificent Seven" stocks. This group's rise has driven its collective share of the S&P 500's value to about 33%, according to research from The Motley Fool.

But which of the high-profile technology companies in the "Magnificent Seven" is reporting the fastest revenue and profit growth?

Image source: Getty Images.

Investors are currently witnessing an unprecedented artificial intelligence (AI) build-out. Cloud computing platforms, AI labs, and even governments need access to powerful graphics processing units to train and deploy AI models. Nvidia (NVDA +2.66%) is the winner of this trend.

The top AI stock posted unbelievable year-over-year revenue growth of 85% in its fiscal 2027 first quarter (ended April 26). Demand for its chips has been off the charts. And management doesn't think the party will stop. Chief financial officer Colette Kress said on the earnings call that AI infrastructure spending will total $3 trillion to $4 trillion by the end of the decade.

Today's Change

(

2.66

%) $

5.19

Current Price

$

200.16

Nvidia's profit gains have been even more impressive. In Q1, the company's diluted earnings per share skyrocketed 214%. This bottom-line metric is up an astonishing 2,815% since the first quarter of fiscal 2024 three years ago, as the business sits in the driver's seat of the ongoing AI boom.

These incredible financial gains have made Nvidia the world's most valuable company, with a market cap of $4.7 trillion.

Neil Patel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy.
2026-07-01 12:03 1mo ago
2026-07-01 06:07 1mo ago
How Nvidia Stock Is Trading Today
NVDA Nvidia
FMP Stock News
Original source text
Nvidia stock is still looking to establish a floor around the $200 level amid a recent selloff.
2026-07-01 12:03 1mo ago
2026-07-01 07:19 1mo ago
Trading expert sets date when Nvidia stock will crash to $165
NVDA Nvidia
FMP Stock News
Original source text
Technical analyst TradingShot has projected a possible $165 drop in Nvidia (NASDAQ: NVDA) stock, with the decline expected by late August 2026.

The Nvidia stock crash prediction, shared in a TradingView post on June 30, is based on a weekly ascending triangle pattern currently in its bearish leg, the same setup that preceded a similar move in February 2025.

Notably, Nvidia stock is rebounding this week after nearly touching its one-week 50-period moving average for the first time since the week of March 30, 2026.

NVDA stock price analysis chart. Source: TradingView TradingShot stated that this bounce mirrors the one from February 2025, which also occurred during the bearish leg of the same ascending triangle structure. In this line, Nvidia ended the last trading session up more than 2% at $200.

Significance of NVDA stock at $165 According to TradingShot, both fractals show identical weekly RSI sequences. Based on that repeating pattern, the next target before any sustainable rebound can be discussed is the one-week 100-period moving average, which aligns with support at $165.

That level previously acted as a floor earlier in the ascending triangle, making it a technical target rather than an arbitrary figure.

At the same time, Nvidia’s weekly chart has formed a broader ascending triangle since 2024, marked by higher highs against a flatter support line.

The pattern has repeated twice: through the 2024-to-early-2025 uptrend and again during the 2025-to-2026 rally that pushed NVDA above $230 in May 2026 before pulling back.

In both cases, the price tested the rising trendline, pulled back, bounced off the one-week MA50, and then continued toward the one-week MA100 and support. TradingShot’s analysis places Nvidia in the early stage of that same sequence now.

A weekly close back above the $230 highs would weaken the bearish case and favor continuation of the broader uptrend. 

A break below $165 support, on the other hand, would open the door to a deeper move toward the one-week 200-period moving average, a level not tested since the triangle began forming.

Nvidia’s strong fundamentals Interestingly, the pullback stands in contrast to Nvidia’s underlying financial performance. Latest-quarter revenue grew 85% year over year, with adjusted earnings rising 139%, while the company posted an adjusted net margin of 55.7%.

For full fiscal 2026, revenue reached $215.9 billion, up 65% from the prior year, including fourth-quarter revenue of $68.1 billion, a 73% year-over-year increase. 

CEO Jensen Huang pointed to exponential growth in computing demand tied to agentic AI adoption, with the Blackwell platform reducing the cost per token by an order of magnitude compared with prior generations.

Nvidia is also projecting $3 trillion to $4 trillion in industry-wide data center capital expenditure by 2030.
2026-07-01 12:03 1mo ago
2026-07-01 07:26 1mo ago
AI predicts Nvidia stock price for July 31, 2026
NVDA Nvidia
FMP Stock News
Original source text
Following the steep correction in June, Nvidia (NASDAQ: NVDA) stock price is set to remain flat by July 31, 2026, per the prediction made on July 1 by the Finbold AI Agent.

Specifically, after using multiple technical analysis (TA) tools, including the relative strength index (RSI), moving averages (MA), and stochastic oscillators, the predictive artificial intelligence (AI) tool estimated that NVDA shares would fall 0.16% to $199.55 from the press-time extended-session price of $199.87.

Finbold AI sets Nvidia stock price target for July 31, 2026. Source: Finbold Notably, the average prediction that Nvidia’s stock price will remain effectively flat by July 31 is the result of a sharp divergence in forecasts among the five models included in the system.

Indeed, Anthropic’s Claude Opus 4.6 proved significantly more bullish than the overall target, estimating NVDA would climb 4.32% to $208.50.

Claude AI sets Nvidia stock price target for July 31, 2026. Source: Finbold On the other end of the spectrum, Google’s (NASDAQ: GOOGL) Gemini 3 Flash was, by far, the most bearish as it forecasted a further 4.21% drop to $191.45.

Google AI sets Nvidia stock price target for July 31, 2026. Source: Finbold xAI’s Grok 4.1, for its part, was closer to the analysis made by Alphabet’s AI given its $192.50 target after a 3.69% correction. OpenAI’s flagship platform, ChatGPT-5.2, was closer to Claude with a 2.72% predicted rally to $205.30.

Lastly, DeepSeek was remarkably close to the average with a prediction that Nvidia stock will remain effectively flat – or, more precisely, that it will rise 0.07% to $200.

Nvidia stock price chart Meanwhile, June proved to be a red month for NVDA shares, as it led to a 10.82% stock price drop from $224.36 at the June 1 close to $200.09 on June 30, and to an overall $588 billion market capitalization wipe.

Nvidia stock price one-month chart. Source: Google The downturn appears to have been driven by a destabilization of the AI boom narrative triggered by the rising debate on the technology’s costs and benefits, but also a rotation to more up-and-coming sectors like memory and even into smaller semiconductor companies like AMD (NASDAQ: AMD) and Intel (NASDAQ: INTC).

Still, despite the decline, Nvidia remains significantly above the March lows and is still in the green in 2026, with the year-to-date (YTD) chart showing an overall 5.95% rally.

Featured image via Shutterstock

Best Crypto Exchange for Intermediate Traders and Investors

Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

Copy top-performing traders in real time, automatically.

eToro USA is registered with FINRA for securities trading.

30+ million Users worldwide

eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more.

Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!
2026-07-01 12:03 1mo ago
2026-07-01 07:11 1mo ago
Bank of America Likely To Report Higher Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
BAC Bank of America
FMP Stock News
Original source text
Bank of America Corporation (NYSE:BAC) will release its second quarter earnings report before the opening bell on Tuesday, July 14.

Analysts expect the Charlotte, North Carolina-based company to report quarterly earnings of $1.10 per share, up from 89 cents per share in the year-ago period. The consensus estimate for Bank of America’s quarterly revenue is $30.26 billion. It reported $26.46 billion last year, according to Benzinga Pro.

On June 29, Bank of America agreed to pay $7.5 million to settle SEC’s alleged charges against Merrill Lynch.

Bank of America shares fell 1.6% to close at $56.98 on Tuesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

Considering buying BAC stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.
2026-07-01 12:02 1mo ago
2026-07-01 07:30 1mo ago
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
JNJ Johnson & Johnson
FMP Stock News
Original source text
Choosing between Bristol Myers Squibb (BMY 1.62%) and Johnson & Johnson (JNJ 1.64%) means deciding whether you prefer a pure-play pharmaceutical company trading at a deep discount or a diversified giant with higher growth.

While both operate within the same broader sector, their business models differ significantly. Bristol Myers focuses heavily on drug development for serious diseases, while Johnson & Johnson splits its attention between medicine and medical devices. Let’s compare them and weigh their specific risks and financial health.

Bristol Myers operates as a major player in the pharmaceutical stocks space, focusing on oncology, hematology, and immunology. The company sells its innovative medicines primarily to wholesalers and specialty pharmacies, relying on established distribution channels for top products like Opdivo and Eliquis. Key commercial alliances with Merck (MRK 0.87%) and BioNTech (BNTX 1.28%) help Bristol Myers expand its reach in specialized therapeutic areas.

In fiscal 2025, revenue reached nearly $48.2 billion, reflecting a slight decrease of approximately 0.2% compared to the previous year. The company reported net income of roughly $7.1 billion during this period, resulting in a net margin of approximately 14.6%. This was a significant recovery from the prior fiscal year, when Bristol Myers recorded a substantial net loss following specific business shifts.

As of its December 2025 balance sheet, the debt-to-equity ratio is roughly 2.6. This figure, which compares total debt to the value of shareholder equity, suggests a higher reliance on borrowed funds. The current ratio, which measures the company's ability to cover short-term debts with current assets, is approximately 1.3, while free cash flow reached nearly $12.8 billion.

The case for Johnson & JohnsonJohnson & Johnson operates through two primary segments: Innovative Medicine and MedTech. The MedTech division serves hospitals and surgical centers with products for orthopedics and vision, while the medicine segment focuses on immunology and oncology. This dual-pronged strategy allows the company to serve a vast range of patients and healthcare professionals globally.

In fiscal 2025, revenue reached approximately $94.2 billion, up nearly 6% year over year. Net income was roughly $26.8 billion, which was a notable increase from the prior year. This resulted in a net margin of approximately 28.5%, which calculates the percentage of revenue remaining after all expenses are paid.

According to J&J’s December 2025 balance sheet, the debt-to-equity ratio is approximately 0.6. This indicates that the company uses significantly less debt relative to its equity than many of its industry peers. The current ratio is roughly 1.0, and the company generated close to $19.7 billion in free cash flow, which is the cash remaining after paying for operations and equipment.

Risk profile comparisonBristol Myers Squibb faces significant pricing pressures from the Inflation Reduction Act, which allows for government-negotiated prices on key drugs like Eliquis. The company also faces the loss of market exclusivity for older brands like Revlimid, which opens the door for cheaper generics. Success depends heavily on the pipeline of new products, as any delays in clinical trials or regulatory hurdles could hurt future earnings.

Johnson & Johnson continues to manage significant litigation risks regarding its talc-containing products, which could impact financial results. The company also faces rising competition from biosimilars produced by companies like Amgen (AMGN +0.40%), particularly affecting its top-selling drug, Stelara. Furthermore, the planned separation of its orthopedics business introduces execution risks and potential stock price volatility during the transition period.

Valuation comparisonBristol Myers Squibb currently trades at a significant discount compared to Johnson & Johnson and the broader sector based on future earnings estimates.

MetricBristol Myers SquibbJohnson & JohnsonSector BenchmarkForward P/E9.122.024.8P/S ratio2.46.5Sector benchmark uses the SPDR XLV sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?Bristol Myers' deep-value valuation looks attractive here. The drugmaker also has what it calls a "Growth Portfolio," which looks strong even as the company loses exclusivity for drugs like Revlimid. Furthermore, the fiscal Q4 update included positive information on several pipeline drugs.

J&J's ongoing talc issues kind of astound me. Put another way, they've been happening for so long that I'm surprised the legal ramifications haven't yet been resolved. And it's not over; it's not even close. There are still 60,000 unresolved cases in the U.S. As recently as this April, it was set to become the largest product liability case in the U.K. ever after additional claimants were added. Even more astounding is that the company faced lawsuits beginning in 2009 but did not phase talc out of its baby powder products for more than a decade, long after incurring massive legal costs. Apart from selling products that allegedly cause cancer, which is bad in and of itself (obviously), this all suggests management is inept.

In other words, hardest of passes on J&J. Bristol Myers has a far more attractive valuation and doesn't face the legal liability J&J does. It's not really a hard choice here.
2026-07-01 12:01 1mo ago
2026-07-01 07:28 1mo ago
Home Depot vs. RH: Which Consumer Stock Is a Better Buy in 2026?
HD Home Depot
FMP Stock News
Original source text
Deciding between a reliable home improvement giant and a high-end luxury disruptor depends on your appetite for risk and growth. Here is how Home Depot (HD +0.51%) and RH (RH +0.70%) stack up today.

Home Depot dominates the broad DIY and professional markets with massive scale, while RH targets the affluent luxury lifestyle segment through international expansion and hospitality. Investors compare them because both rely on the health of the retail sector and broader housing trends to drive sales growth.

The case for Home DepotHome Depot operates as a home improvement specialty retailer serving DIY customers and professional contractors, such as renovators and trade professionals. The business supports these groups through an interconnected network of stores and digital platforms across North America. These moves help the company capture more share among retail stocks by targeting complex project needs through its acquisitions of SRS and GMS.

In FY 2025, revenue reached nearly $164.7 billion, representing growth of approximately 3.2% over the previous year. Net income for the fiscal period was close to $14.2 billion. This figure was slightly lower than the roughly $14.8 billion recorded in FY 2024, reflecting a slight contraction in net margin from 9.3% to 8.6%.

As of its February 2026 balance sheet, the debt-to-equity ratio is approximately 5.1x, meaning total debt, including short-term and long-term borrowings, is 5.1 times the value of shareholder equity. The current ratio, which measures a company's ability to cover short-term debts with short-term assets, is roughly 1.1x. Free cash flow, calculated as cash flow from operations minus capital expenditures, was nearly $12.6 billion during the year.

The case for RHRH functions as a luxury lifestyle brand, offering high-end home furnishings through a unique ecosystem of galleries and sourcebooks. The company is actively expanding its international footprint and diversifying into hospitality experiences like restaurants and luxury guesthouses. These initiatives aim to transform the brand into a comprehensive luxury lifestyle provider that serves a high-end consumer base and professional interior designers.

For FY 2025, revenue reached $3.4 billion, indicating growth of about 8.1% compared to the prior year. Net income reached approximately $124.8 million during the same period. This was an increase from the roughly $72.4 million in net income reported for FY 2024, showing progress in the company's turnaround efforts.

As of its January 2026 balance sheet, the debt-to-equity ratio is roughly 65.5x, meaning total debt, including short-term and long-term borrowings, is much higher than shareholder equity. The current ratio, which also measures the ability to pay short-term debts with current assets, is approximately 1.2x. Free cash flow, defined as cash flow from operations minus capital expenditures, reached close to $252.4 million.

Risk profile comparisonHome Depot faces intense competition from digital retailers like Amazon and must adapt to shifting consumer preferences and shopping habits. The company also deals with high sensitivity to housing market volatility and shifting tariff policies that affect commodity costs.

RH manages significant execution risks as it develops hospitality concepts and expands into complex real estate projects internationally. The business also carries substantial financial leverage and depends on foreign manufacturing in Asia, which exposes it to supply chain disruptions and trade duties.

Valuation comparisonRH carries a higher forward P/E, which measures price against future earnings estimates, while its P/S ratio compares market value to sales.

MetricHome DepotRhSector BenchmarkForward P/E23.3x32.3x28.6xP/S ratio2.1x0.9xN/ASector benchmark uses the SPDR XLY sector ETF. Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Home Depot and RH both depend on the demand trends of the housing sector, which tend to be cyclical and tied closely to interest rates. High interest rates and inflation pressure have challenged both stocks, with Home Depot down about 3% over the last year on a total return basis and RH losing a larger 17%, as of July 1. Over the past five years, Home Depot has returned a gain of 25% while RH has demonstrated an even steeper decline: down 76%. While past results don’t guarantee future performance, the disparity points to the key ideological difference between Home Depot and RH stocks.

Home Depot has long been cited as a relatively safe investment — catering to both retail customers and professional contractors, enjoying a wide geographic reach within the U.S., and paying a 2.64% dividend that rewards patient investors. Indeed, without the dividend reinvested, Home Depot’s five-year performance drops to just shy of a 10% gain. It’s probably a better bet than RH for investors who are looking for stability and income, but it’s unlikely to deliver blockbuster results.

The case for RH is similar to that of American Express: It caters to a wealthier, more exclusive clientele that tends to have more consistent and higher spending regardless of economic conditions. Its luxury brand is its own kind of moat, and it’s still in growth mode, taking on substantial debt now to build a brand that could pay off big-time down the road. If you’re willing to bet on the story, it could be an attractive time to buy in, but the future appears murky and isn’t without risk.
2026-07-01 12:00 1mo ago
2026-07-01 07:00 1mo ago
Short Squeeze Alert—Moderna Stock Surges on New Strategy
MRNA Moderna
FMP Stock News
Original source text
Moderna Today

$70.03 +0.33 (+0.47%)

As of 06/30/2026 04:00 PM Eastern

52-Week Range$22.28▼

$73.28Price Target$37.13

Shares of Moderna NASDAQ: MRNA are behaving like it's 2020. The stock is up nearly 20% since the company’s Science Day event.

At that time, Moderna revealed its strategy for using mRNA to combat cancer and rare diseases. It’s a move beyond vaccines, and investors seem to like it.

Get Moderna alerts:

Looks, however, can be deceiving. Prior to the event, MRNA had short interest of over 16.5% which required over 10 days for short sellers to cover their positions.

The result? A classic short squeeze that has sent the stock to nearly double its consensus price target of around $37 as of June 30.

However, the price movement by itself isn’t disqualifying. The expansion of mRNA as a treatment for diseases is where the promise has always been. Therefore, investors are left with a decision ahead of its Q2 2026 earnings report, scheduled for July 30.

Why mRNA Still MattersThe promise of mRNA is that it changes how medicine gets made. Traditional drugs are manufactured in factories and injected into the body. mRNA medicines work differently. They deliver genetic instructions, and the body's own cells produce the protein needed to treat the disease.

That matters for two reasons. The same platform can be reprogrammed for different diseases by changing only the instructions. And that flexibility could make drug development faster and more efficient over time.

COVID-19 vaccines proved the platform works in infectious disease. The question Moderna is now trying to answer is whether the same approach can deliver meaningful results for cancer, autoimmune diseases, and rare diseases.

If the answer is yes, the platform becomes far more valuable than its vaccine franchise alone. That's the long-term story driving the recent move.

3 Horizons, 1 Long RunwayAt Science Day, Moderna organized its business into three "Horizons" that map how the platform scales over time.

Horizon 1 is Moderna’s commercial engine. It includes four approved vaccines (Spikevax, mRESVIA, mNEXSPIKE, and mCOMBRIAX), the investigational intismeran autogene cancer therapy, and a rare disease franchise led by a propionic acidemia treatment. This accounts for the bulk of the company’s current revenue.

Horizon 2 is the next wave. T-cell engagers targeting multiple myeloma and ovarian cancer, cancer antigen therapies for solid tumors and Lynch syndrome, and a multiple sclerosis therapeutic linked to the Epstein-Barr virus. Most are in Phase 1 or Phase 2 trials. The earliest meaningful readout is mRNA-1195 for multiple sclerosis, which is expected in the second half of 2026.

Horizon 3 is the long-term bet. The headline asset is mRNA-6007, an in vivo CAR-T therapy aimed at lupus. Moderna expects this to enter human trials by the end of 2027.

That’s a whole lot of potential. However, none of Horizon 2 or Horizon 3 will generate revenue until after 2028. Phase 1 and Phase 2 readouts are clinical milestones, not commercial ones. The path from trial to approval to launch takes years.

Why Caution Is WarrantedOn June 26, the day after Moderna’s Science Day event, Piper Sandler reiterated its Overweight rating on MRNA and raised its price target to $77 from $69. Even at the former price target, Piper Sandler was already one of the most bullish analysts.

It’s important to note, however, that the new price target doesn’t leave much upside for MRNA after its recent gains. Analysts may be holding off on issuing opinions until the company’s earnings report, especially since there won’t be any revenue or earnings from these new initiatives for several years.

That puts the entire burden on Horizon 1. The four approved vaccines, the intismeran Phase 3 program, and disciplined cash management have to fund the pipeline long enough for the platform story to pay off.

That’s why long-term investors who aren’t in the stock should wait for a better entry point. It’s also a reason for current shareholders to take some risk off the table.

Where the Squeeze Logically Gives BackThe most likely first pullback level is $60. It's a round-number psychological level and represents a healthy give-back of about half the move off the mid-June breakout. Pullbacks of that size are normal after a sharp rally; they are normal profit-taking and leave the bullish structure intact.  Anyone trimming into the squeeze would look to add back near this level.

The deeper, higher-conviction support is $55. That was the top of the April-to-June trading range, and the launch point of the Science Day breakout candle. Prior resistance becomes new support, and this is where the squeeze froth fully resets without breaking the thesis.

The line in the sand is $52, where the 50-day SMA sits at $51.83. A close below that level would mean the breakout has failed, and the stock has fallen back into the range it traded in before Science Day. At that point, the platform re-rate needs a fresh catalyst, such as the July 30 earnings report, to reassert itself.

Should You Invest $1,000 in Moderna Right Now?Before you consider Moderna, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.

While Moderna currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
2026-07-01 12:00 1mo ago
2026-07-01 06:31 1mo ago
What's Going on With Intel Stock Wednesday?
INTC Intel
FMP Stock News
Original source text
Nasdaq futures were down 0.54%, while S&P 500 futures slipped 0.31%, weighing on technology stocks ahead of the opening bell.

Intel appeared to be facing profit-taking after a strong rally that pushed the stock close to its 52-week high.

The stock has significantly outperformed the broader market over the past year. That leaves it vulnerable to short-term selling when investor sentiment weakens.

With shares trading well above their major moving averages, traders may also be locking in gains as the market shifts toward a more risk-off tone.

Intel Emerges as a Major AI WinnerCNBC reported that the three companies added roughly $2 trillion in combined market capitalization during the quarter, making them the 10th-, 11th- and 12th-most valuable U.S. technology companies. Intel shares surged 216% during the quarter, adding about $480 billion to the company’s market value.

Analysts See Rotation Into AI InfrastructureBarclays analyst Anshul Gupta told CNBC that investors rotated money out of AI hyperscalers and into companies supplying the hardware needed to build AI infrastructure.

That shift fueled sharp gains across semiconductor stocks as investors looked beyond AI chip leaders to companies positioned to benefit from rising data center investment.

Analysts told CNBC the rally could represent a “changing of the guard in AI,” with investors favoring companies that complement NVIDIA’s ecosystem rather than compete directly with it.

Cramer Says Intel Is His Favorite Tech WinnerCNBC’s Jim Cramer highlighted Intel as one of the standout technology performers of the second quarter, crediting CEO Lip-Bu Tan with transforming the company’s outlook.

Cramer called Intel his favorite stock among the quarter’s biggest technology winners.

He said investors are rewarding companies that produce technology in short supply while large technology customers continue spending aggressively to support AI expansion.

He identified three major growth drivers for Intel: its leadership in CPUs that power AI agents, its higher-margin chip packaging business, and its expanding foundry operations.

Cramer also said Intel could eventually help ease the industry’s memory shortage and described the company as “a national treasure.”

Technical Picture Remains BullishDespite the premarket decline, Intel’s longer-term trend remains positive.

The stock is trading about 13% above its 20-day simple moving average of $121.79 and roughly 132% above its 200-day simple moving average of $59.34. The 20-day average remains above the 50-day average, while the 50-day average is above the 200-day average, a bullish alignment that often supports buy-the-dip activity.

Momentum indicators also remain constructive. The MACD is above its signal line, and the histogram remains positive, suggesting upward momentum continues even as the stock consolidates.

Traders are watching resistance near $141.50. A sustained move above that level could open the door to a test of the 52-week high of $142.35.

Earnings Remain the Next Key CatalystIntel is scheduled to report second-quarter earnings on July 23.

Analysts expect earnings of 19 cents per share, compared with a loss of 10 cents a year earlier. Revenue is projected to rise to $14.40 billion from $12.86 billion in the prior-year period.

Wall Street currently has a consensus Hold rating on the stock with an average price forecast of $88.63.

Recent analyst actions include Cantor Fitzgerald raising its price forecast to $150 while maintaining a Neutral rating on June 29, Goldman Sachs initiating coverage with a Neutral rating and a $150 price forecast on June 25, and Bank of America Securities raising its price forecast to $160 while reiterating a Buy rating on June 23.

Top ETF ExposureINTC Stock Price Activity: Intel shares were down 1.57% at $137.44 during premarket trading on Wednesday, according to Benzinga Pro data.

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.
2026-07-01 11:59 1mo ago
2026-07-01 06:45 1mo ago
Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4
MRK.US Merck & Company
FMP Stock News
Original source text
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, Aug. 4. During the call, company executives will provide an overview of Merck’s performance for the quarter.

Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com.

All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Free) or (517) 308-9448 and using the access code 9818590.

About Merck

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

More News From Merck & Co., Inc.
2026-07-01 11:59 1mo ago
2026-07-01 06:07 1mo ago
MGM Investigation Notification: The MGM Resorts Proposed Transaction is being Investigated – Contact BFA Law if You Hold Shares
MGM MGM Resorts International
FMP Stock News
Original source text
NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating Barry Diller’s bid to buy MGM Resorts International (NYSE:MGM). MGM is incorporated in Delaware.

Barry Diller is a member of MGM’s board of directors. People, Inc. (“People,” f/k/a/ IAC, Inc.), a company that Diller founded and controls, is MGM’s largest single stockholder. On June 1, 2026, People made an unsolicited bid to buy the remaining MGM stock for $48.30 per share.

If you are a current shareholder of MGM, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/mgm-resorts-investigation.

Key Details of the MGM ($MGM) Investigation:

Investigation Overview: Breaches of Fiduciary Duty in connection with Barry Diller’s offer to acquire the remaining stock of MGM for $48.30 per shareAction: Contact BFA Law to discuss your rights Why is the MGM Transaction being Investigated?

As a director, Diller owes fiduciary duties to MGM and its stockholders. People also recently entered a governance agreement with MGM that gave People the right to designate two MGM directors going forward.   Because Diller “stands on both sides” of the proposed deal, and because other MGM fiduciaries could potentially receive benefits that other stockholders do not receive, these facts create a create conflicts of interest under Delaware law. If MGM and Diller reach an agreement, they must comply with Delaware’s strict requirements for “cleansing” these conflicts and ensuring the deal is fair to MGM’s stockholders.

In a news release on June 1, MGM stated that the board of directors “will carefully review and consider the proposal to determine the course of action that it believes is in the best interests of the Company and all of its shareholders.”  

BFA is investigating whether the potential agreement complies with Delaware law.

Click here for more information:

https://www.bfalaw.com/cases/mgm-resorts-investigation

What Can You Do?

If you are a current holder of MGM stock, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/mgm-resorts-investigation

Or contact:

Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/mgm-resorts-investigation

Attorney advertising. Past results do not guarantee future outcomes.
2026-07-01 11:58 1mo ago
2026-07-01 06:00 1mo ago
Linde Announces Second Quarter 2026 Earnings and Conference Call Schedule
LIN Linde
FMP Stock News
Original source text
WOKING, England--(BUSINESS WIRE)--Linde (Nasdaq: LIN) will release its second quarter 2026 financial results by 06:00 EDT/midday CEST on Friday, July 31, 2026. The Company will host and webcast its conference call at 09:00 EDT/15:00 CEST, which will be available to the public and the media in listen-only mode. Live conference call US Toll-Free Dial-In Number: 1 888 770 7292 UK Toll-Free Dial-In Number: 0800 358 0970 Access code: 6877110   Live webcast (listen-only)   https://www.linde.com/inves.
2026-07-01 11:57 1mo ago
2026-07-01 07:45 1mo ago
The Safest Dividend Plays of 2026: 5 High-Yield, Low-PE Dividend Aristocrats
SWK Stanley Black & Decker
FMP Stock News
Original source text
The S&P 500 is up about 10% this year, yet 80% of that gain comes from technology stocks, many of which are tied to artificial intelligence. With interest rates and energy prices spiraling higher, and inflation clearly not under control, those willing to put any new money to work in stocks should likely be extremely careful. Why, you ask? The Shiller P/E, which compares the market’s price to average inflation-adjusted earnings over the trailing decade, currently sits at 41. This is the highest the Shiller P/E has been since the dot-com bubble peak, which reached roughly 44 in 1999. Both levels are significantly above the long-term historical average of around 17.

Investors seeking defensive companies that pay substantial dividends are drawn to the Dividend Aristocrats, and with good reason. The 69 companies that made the cut for the 2026 S&P 500 Dividend Aristocrats list have increased their dividends (not just maintained them) for 25 consecutive years. But the requirements go even further, with the following attributes also mandatory for membership on the aristocrats list:

Companies must be worth at least $3 billion for each quarterly rebalancing. Their average daily trading volume must be at least $5 million in transactions for every trailing three-month period at every quarterly rebalancing date. They must be a member of the S&P 500. We screened the 2026 Dividend Aristocrats to identify companies trading at the best price-to-earnings ratios and found five that also pay among the highest dividends in the group. All are rated Buy at top firms we cover on Wall Street, and all make sense for growth and income investors worried about the current state of the stock market.

Why do we cover the Dividend Aristocrats?

S&P 500 companies that have paid and raised their dividends for 25 years or longer are the types that growth and income investors want to buy and hold in their stock portfolios for the long term. These stocks are mostly conservative, and should we see a dramatic market correction, they will likely hold their ground much better than volatile technology names, many of which are overbought and frothy.

Hormel Foods Hormel Foods (NYSE: HRL | HRL Price Prediction) is an American food processing company founded in 1891 in Austin, Minnesota. With shares down 14% already in 2026, the stock trades at 13.07 times forward earnings estimates. Hormel offers dual pricing power through both branded products and private-label manufacturing, as well as a reliable 4.7% dividend.

Hormel develops, processes, and distributes a range of meat, nuts, and other food products to retail, foodservice, deli, and commercial customers in the United States and internationally. It operates through three segments:

Retail Food Service International This Dividend Aristocrat is a consumer staples company focused on protein-based packaged foods. Its yield is historically high, and the Hormel Foundation’s oversight ensures dividend reliability. Reports indicate that it is restructuring its portfolio and cutting costs to improve performance.

The company provides various perishable products, including fresh meats, frozen items, refrigerated meal solutions, sausages, hams, guacamole, and bacon, and shelf-stable products, including canned luncheon meats, nut butter, snack nuts, chili, shelf-stable microwaveable meals, hash, stews, tortillas, salsas, tortilla chips, nutritional food supplements, and others. It sells its products under these brands:

Hormel Always Tender Applegate Austin Blues Bacon 1 Black Label Bread Ready Burke Café H Ceratti Chi-Chi’s Columbus Compleats Corn Nuts Cure 81 Dan’s Prize Di Lusso Dinty Moore Don Miguel Doña Maria Embasa Fast N Easy Fire Braised Fontanini Happy Little Plants Herdez Hormel Gatherings Hormel Square Table Hormel Vital Cuisine House of Tsang Jennie-O Justin’s La Victoria Layout Lloyd’s Mary Kitchen Mr. Peanut Natural Choice Nut-rition Old Smokehouse Oven Ready Pillow Pack Planters Rosa Grande Sadler’s Smokehouse Skippy Spam Special Recipe Thick & Easy Valley Fresh Wholly Barclays has an Overweight rating with a $23 target price.

Stanley Black & Decker Stanley Black & Decker (NYSE: SWK) is the world’s largest tool company, with 50 manufacturing facilities in the United States and more than 100 worldwide, and its shares trade at 13.54 times forward earnings estimates. With the potential for the economy to slow down somewhat, you can bet that the do-it-yourself legions will fix rather than buy new, and this legendary stock is a solid idea now, while yielding a large 3.53% dividend.

Stanley Black & Decker provides hand tools, power tools, outdoor products, and related accessories in the United States, Canada, Europe, and elsewhere. Its Tools & Outdoor segment offers professional-grade corded and cordless electric power tools and equipment, including:

Drills Impact wrenches and drivers Grinders, saws, routers, and sanders Pneumatic tools and fasteners, such as nail guns, nails, staplers and staples, and concrete and masonry anchors; corded and cordless electric power tools Hand-held vacuums, paint tools, and cleaning appliances Leveling and layout tools, planes, hammers, demolition tools, clamps, vises, knives, saws, chisels, and industrial and automotive tools Drill, screwdriver, router bits, abrasives, saw blades, and threading products Toolboxes, sawhorses, mechanic cabinets, and engineered storage solutions Electric and gas-powered lawn and garden products This segment sells its products under these brand names:

DeWalt Craftsman Cub Cadet Black+Decker Hustler The company’s Industrial segment provides:

Threaded fasteners, blind rivets and tools, blind inserts and tools Drawn arc weld studs and systems Engineered plastic and mechanical fasteners Self-piercing riveting systems Precision nut running systems Micro fasteners High-strength structural fasteners Axle swage, latches, heat shields, pins, couplings, fittings, and other engineered products Attachments used on excavators and handheld tools This segment sells its products through a direct sales force and third-party distributors to various industries, including automotive, manufacturing, electronics, construction, aerospace, and others.

UBS has a Buy rating on the shares and a $98 target price.

Genuine Parts Investors seeking a solid retail investment should consider purchasing this company, as its products remain in high demand and it has raised the dividend for 69 consecutive years. Genuine Parts (NYSE: GPC) is a global service provider of automotive and industrial replacement parts and value-added solutions, trading at 11.77 times forward earnings estimates with a 3.9% dividend yield.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and PepsiCo didn't make the cut. Grab the names FREE today.

The Automotive segment distributes replacement parts (other than collision parts) for all makes and models of automobiles, trucks, and other vehicles in North America, Europe, and Australasia. Its main automotive customers are repair and maintenance shops, and its main industrial customers are businesses operating distribution, manufacturing, and production equipment.

The Industrial segment distributes a wide variety of industrial bearings, mechanical and fluid power transmission equipment, including:

Hydraulic and pneumatic products Material handling components Related parts and supplies This segment offers replacement parts and solutions to customers in the maintenance, repair, and operation business, as well as to original equipment manufacturers.

Raymond James has a Strong Buy rating on the shares with a $145 target.

PepsiCo This top consumer staples stock reported solid first-quarter earnings and will continue to supply all the goods for summer picnics and parties. PepsiCo (NYSE: PEP) is a global food and beverage company with a very solid 4.08% dividend yield and a forward P/E of 16.92.

Activist investor Elliott Investment Management recently took a $4 billion stake in PepsiCo last September, revealing a strategy to unlock value by focusing on core strengths such as innovation and brand marketing, rather than its capital-intensive bottling operations. This move caused PepsiCo’s stock to surge, with Elliott believing the company could see over 50% upside if its proposed strategic changes were implemented. However, these changes would involve a very long-term transformation.

PepsiCo’s Frito-Lay North America segment offers:

Lays and Ruffles potato chips Doritos, Tostitos, and Santitas tortilla chips Cheetos cheese-flavored snacks, branded dips Fritos corn chips The company’s Quaker Foods North America segment provides:

Quaker Oatmeal Grits Rice cakes Natural granola and oat squares Pearl Milling mixes and syrups Quaker Chewy granola bars Cap’n Crunch cereal Life cereal Rice-A-Roni side dishes PepsiCo’s North America Beverages segment offers beverage concentrates, fountain syrups, and finished goods under these brands:

Pepsi Gatorade Mountain Dew Diet Pepsi Aquafina Diet Mountain Dew Tropicana Pure Premium Sierra Mist Mug Goldman Sachs has a Buy rating with a $183 price objective.

PPG Industries Formerly known as Pittsburgh Paint and Glass, it has paid dividends to shareholders since 1899 and currently offers a 2.30% dividend, trading at a very reasonable 12.83 times forward earnings estimates. PPG Industries (NYSE: PPG) manufactures and distributes paints, coatings, and specialty materials in the United States, Canada, the Asia Pacific, Latin America, Europe, the Middle East, and Africa. It operates through two segments.

The Performance Coatings segment offers:

Coatings Solvents Adhesives Sealants Sundries Software for automotive and commercial transport/fleet repair and refurbishing Light industrial coatings and specialty coatings for signs Wood stains, paints, thermoplastics, pavement marking products, and other advanced technologies for pavement marking for government, commercial infrastructure, painting, and maintenance contractors Coatings, sealants, transparencies, transparent armor, adhesives, engineered materials, and packaging and chemical management services for commercial, military, regional jet, and general aviation aircraft The Industrial Coatings segment offers coatings, adhesives, and sealants, as well as metal pretreatments, services, and coatings applications for:

Appliances, agricultural and construction equipment Consumer electronics, automotive parts, and accessories Building products Kitchenware Vehicles and other finished products. On-site coatings services It also provides coatings for metal cans, closures, plastic and aluminum tubes for food, beverage, and personal care, promotional, and specialty packaging; amorphous precipitated silica for tires, battery separators, and other end-users; TESLIN substrates for labels, e-passports, driver’s licenses, breathable membranes, and loyalty and identification cards; and organic light emitting diode materials, displays and lighting lens materials, optical lenses, color-change products, and photochromic dyes.

Wells Fargo has an Overweight rating with a target price of $130.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and PepsiCo didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.
2026-07-01 11:56 1mo ago
2026-07-01 07:37 1mo ago
Introducing Arbex: a New Global Leader in Tissue and Hygiene
KMB Kimberly-Clark
FMP Stock News
Original source text
LONDON--(BUSINESS WIRE)--Arbex, a new global leader in tissue and hygiene, today commences operations as an independent business and unveils details of its brand, leadership team, and company structure. Announced in June 2025 as a $3.4 billion joint venture between Suzano (NYSE: SUZ), the world’s largest pulp supplier, and Kimberly-Clark Corporation (NASDAQ: KMB), a global leader in consumer goods and personal care, the new business will manufacture, market and distribute consumer and professional products across more than 70 markets on five continents.

Arbex has assumed ownership of assets previously run by Kimberly-Clark’s International Family Care & Professional (IFP) business unit, which includes 22 manufacturing sites in 14 countries, and a portfolio of more than 40 regional brands including Andrex®, Hakle®, and Scottex®. The company also holds a long-term license for the use of Kimberly-Clark’s global brands, including Kleenex®, Cottonelle®, Scott®, WypAll®, Viva®, and Kimberly-Clark Professional.

Ehab Abou-Oaf, previously President of Kimberly-Clark’s IFP business, directly transitions in as Chief Executive Officer of Arbex. He will be based in London, alongside the majority of the global leadership team. Luís Bueno, previously Executive Vice President of Suzano’s consumer goods business, becomes Chief Operating Officer. And Oscar Mousinho, a Kimberly-Clark veteran who most recently served as Global CFO of the Pet Nutrition business at Mars, is the incoming Chief Financial Officer. Walter Schalka, who spent over a decade as CEO of Suzano before stepping down in 2024, will chair Arbex’s Board of Directors.

Ehab Abou-Oaf, CEO of Arbex, said:

“This new company brings together a distinguished heritage, a portfolio of trusted brands, and a compelling vision for the future. Our parent companies have given us a sturdy foundation and a leading market position. In an increasingly dynamic and evolving global landscape, Arbex is embarking on a new journey from a position of strength, and we believe we can shape the future of the tissue and hygiene sector.

“Our immediate priority is ensuring a smooth and seamless transition for our colleagues, customers and consumers around the world. Our team will work hard to grow our business, continuing to earn the trust of hundreds of millions of households worldwide who use our products every day, and remaining committed to delivering quality, sustainability and value.”

Luís Renato Bueno, Chief Operating Officer of Arbex, said:

“Arbex brings together world-class talent with brands that already hold significant market share in over 70 countries around the world. From day one we will be a successful global business, which gives us an exciting launchpad for accelerated growth and an opportunity to build on momentum.

“We are combining the best of Suzano’s industrial and operational expertise, with Kimberly-Clark’s formidable international marketing and brand capabilities – uniting these through shared values of innovation and sustainability. With a pure-play focus on tissue and hygiene products, we believe Arbex has commercial, technical and innovation capabilities that can deliver top-line and bottom-line improvements, helping make us the undisputed global leader in our sector.”

NOTES TO EDITOR

About Arbex

Arbex is a leading global tissue and hygiene business, that is home to some of the world’s most trusted consumer brands. We have a portfolio of household and professional products sold in more than 70 countries, including Kleenex, Scott, Cottonelle, WypAll, Andrex and Viva.

Arbex is joint venture between Suzano, the world’s largest pulp supplier, and Kimberly-Clark, a global leader in consumer goods and personal care. We combine local market insight with global scale and expertise, with 22 manufacturing facilities across 14 countries on five continents.

Learn more at arbex.com

Announced appointments to the senior leadership team of Arbex include:

Ehab Abu-Oaf, Chief Executive Officer (formerly President, International Family Care & Professional, Kimberly-Clark) Luís Renato Bueno, Chief Operating Officer (formerly Executive Vice President Consumer Goods, Suzano) Oscar Mousinho, Chief Financial Officer (formerly Global Chief Financial Officer Pet Nutrition, Mars) Caroline Carpenedo, Chief People, Sustainability, Communications & Corporate Brand Officer (formerly Executive Vice President, People & Management, Safety, Suzano) Chris Burniston, Chief Legal Counsel (formerly Vice President & General Counsel, International Family Care & Professional, Kimberly-Clark) Andrew Behles, Chief of Strategy & Transformation Officer (formerly Senior Director, FP&A and Strategy, Chief of Staff, International Family Care & Professional, Kimberly-Clark) Fiona Emmett, Chief Growth Officer (formerly Vice President International Family Care & Professional Growth, Kimberly-Clark) Pablo Cadaval, Chief Technology Officer, Supply Chain and R&D (formerly R&D Director, Head of R&D, Suzano) Dan Howell, President, Europe (formerly Managing Director & Vice President UK & Ireland, International Family Care & Professional, Kimberly-Clark) Rez Hassan, President, Asia, (formerly Managing Director & Vice President Asia, International Family Care & Professional, Kimberly-Clark) Marina Negrisoli, President, Latin America (formerly Joint Venture Integration Office Director, Suzano) Mark Taylor, President, UK & Ireland (formerly Commercial Director UK & Ireland, International Family Care & Professional, Kimberly-Clark) About Suzano

Suzano is the world's largest pulp supplier, a major paper and packaging producer in the Americas, and one of Brazil’s biggest employers.

Driven by a deep commitment to sustainability and innovation, Suzano produces responsibly-grown raw materials that are exported to more than 100 countries around the world. These are used to make everyday items that reach more than two billion people, including toilet paper and tissue, packaging, printing and writing paper, personal hygiene products, and textiles.

Founded in Brazil over 100 years ago, today Suzano operates across Latin America, North America, Europe and Asia. The company’s shares are listed on the B3 in São Paulo (SUZB3) and the New York Stock Exchange (SUZ).

Learn more at: suzano.com.br/en

About Kimberly-Clark

Kimberly-Clark (NASDAQ: KMB) and its trusted brands are an indispensable part of life for people in more than 175 countries and territories. Our portfolio of brands, including Huggies, Kleenex, Scott, Kotex, Cottonelle, Poise, Depend, Pull-Ups, Goodnites, Intimus, Plenitud, Sweety, Softex, Viva and WypAll, hold No. 1 or No. 2 share positions in approximately 70 countries. Our company's purpose is to deliver Better Care for a Better World. We are committed to using sustainable practices designed to support a healthy planet, build strong communities, and enable our business to thrive for decades to come. To keep up with the latest news and learn more about the company's more than 150-year history of innovation, visit the Kimberly-Clark website.
2026-07-01 11:56 1mo ago
2026-07-01 07:00 1mo ago
General Mills Reports Fiscal 2026 Fourth-quarter Adjusted Results in Line with Company Expectations
GIS General Mills
FMP Stock News
Original source text
MINNEAPOLIS--(BUSINESS WIRE)--General Mills, Inc. (NYSE: GIS) today reported results for its fourth quarter and fiscal year ended May 31, 2026. Fiscal 2026 was a 53-week year, with the extra week falling in the fourth quarter.

“We finished fiscal 2026 on a positive note, delivering fourth-quarter adjusted results that met our expectations while continuing to strengthen our foundation to position General Mills for long-term success,” said General Mills Chairman and Chief Executive Officer Jeff Harmening. “With our price investment work behind us, our focus in fiscal 2027 is to improve our topline growth by driving a step change in the remarkability of our brands. This includes a significant increase in innovation and renovation centered on the benefits that matter most to today’s consumers.

“At the same time, we are laser focused on increasing our efficiency to help offset elevated inflation, fund our growth investments, and generate stronger earnings and cash flow,” Harmening continued. “We’re targeting $3 billion in cumulative cost savings by fiscal 2030, primarily through our Holistic Margin Management productivity program and our global transformation initiative, with $750 million expected to be delivered in fiscal 2027.

“With plans to strengthen our remarkability and a sharp focus on efficiency and capital discipline, I’m confident we’re on the path to restoring profitable growth and driving shareholder value over the long term.”

Guided by its Accelerate strategy, General Mills is investing in its brands to restore profitable organic net sales growth, with initiatives that touch all elements of the company’s Remarkable Experience Framework: product, packaging, brand communication, omnichannel execution, and consumer value. With a stronger foundation of brand remarkability, General Mills believes it is better positioned to deliver stronger, more sustainable, and more profitable growth and value creation over the long term.

Fourth Quarter Results Summary

Net sales were up 1 percent to $4.6 billion, including a 7-point benefit from the 53rd week, a 1-point benefit from foreign currency exchange, and a 7-point headwind from the net impact of divestitures and acquisitions. Organic net sales were flat, including a 1-point benefit from favorable trade expense timing. Gross margin increased 240 basis points to 34.8 percent of net sales, driven by favorable net price realization and mix and favorable mark-to-market effects, partially offset by higher input costs. Adjusted gross margin increased 150 basis points to 34.2 percent of net sales, driven by favorable net price realization and mix, partially offset by higher input costs. Favorable trade expense timing was a 60-basis point benefit to adjusted gross margin in the quarter. Operating loss totaled $2.1 billion compared to operating profit of $504 million a year ago. The change in operating profit was due primarily to $1.8 billion in non-cash goodwill and brand intangible asset charges driven primarily by an increase in discount rates (please see Note 3 below for more information on these items) and a $1.0 billion non-cash pre-tax valuation loss related to the planned divestiture of the Brazil business (please see Note 2 below for more information on this item). Operating profit margin was (45.4) percent compared to 11.1 percent a year ago. Adjusted operating profit of $705 million was up 13 percent in constant currency, driven by higher adjusted gross profit dollars including a 7-point benefit from favorable trade expense timing. Adjusted operating profit margin increased 160 basis points to 15.3 percent. Net loss attributable to General Mills totaled $2.0 billion and diluted loss per share was $3.74 compared to net earnings of $294 million and diluted EPS of $0.53 last year, driven primarily by lower operating profit. Adjusted diluted EPS of $0.95 was up 27 percent in constant currency, driven primarily by higher adjusted operating profit, a lower adjusted effective tax rate, and lower net shares outstanding, partially offset by higher net interest expense. Full Year Results Summary

Net sales were down 5 percent to $18.4 billion, including a 6-point headwind from the net impact of divestitures and acquisitions, a 2-point benefit from the 53rd week, and a 1-point benefit from foreign currency exchange. Organic net sales were down 2 percent, due in part to weaker consumer sentiment and significant volatility that weighed on category volume growth and drove a higher share of consumer purchases on promotion. Gross margin was down 100 basis points to 33.6 percent of net sales and adjusted gross margin was down 100 basis points to 33.5 percent of net sales, both driven by higher input costs, partially offset by the favorable impact of net price realization and mix to gross margin, including the product mix benefit from the North American Yogurt divestitures. Operating profit of $886 million was down 73 percent, driven primarily by the goodwill and brand intangible asset charges, the valuation loss, and lower gross profit dollars in fiscal 2026, partially offset by a $1.0 billion gain on the yogurt divestitures (please see Note 2 for more information on this item). Operating profit margin was 4.8 percent compared to 17.0 percent a year ago. Adjusted operating profit of $2.8 billion was down 16 percent in constant currency, driven primarily by lower adjusted gross profit dollars. Adjusted operating profit margin was down 190 basis points to 15.3 percent. Net loss attributable to General Mills totaled $88 million and diluted loss per share was $0.16 compared to net earnings of $2.3 billion and diluted EPS of $4.10 a year ago, driven primarily by lower operating profit, a higher effective tax rate, and lower after-tax earnings from joint ventures, partially offset by lower net shares outstanding. Adjusted diluted EPS of $3.55 was down 16 percent in constant currency, driven primarily by lower adjusted operating profit. Operating Segment Results

The following items impacted the comparability of year-to-date financial results between fiscal 2025 and fiscal 2026: the divestiture of the U.S. Yogurt business in the first quarter of fiscal 2026, the 53rd week in the fourth quarter of fiscal 2026, the divestiture of the Canada Yogurt business in the third quarter of fiscal 2025, and the acquisition of the North American Whitebridge Pet Brands business in the third quarter of fiscal 2025. Tables may not foot due to rounding. Components of Fiscal 2026 Reported Net Sales Growth

Fourth Quarter

Volume

Price/Mix

Foreign

Exchange

Reported

Net Sales

North America Retail

(13) pts

9 pts

--

(4)%

North America Pet

1 pt

3 pts

--

4%

North America Foodservice

--

(1) pt

--

(1)%

International

8 pts

3 pts

5 pts

16%

Total

(4) pts

4 pts

1 pt

1%

Full Year

North America Retail

(16) pts

5 pts

--

(11)%

North America Pet

--

5 pts

--

6%

North America Foodservice

(4) pts

(2) pts

--

(6)%

International

3 pts

2 pts

4 pts

9%

Total

(8) pts

2 pts

1 pt

(5)%

  Components of Fiscal 2026 Organic Net Sales Growth

Fourth Quarter

Organic

Volume

Organic

Price/Mix

Organic

Net Sales

Foreign

Exchange

Acquisitions & Divestitures

53rd Week

Reported

Net Sales

North America Retail

(2) pts

2 pts

Flat

--

(10) pts

7 pts

(4)%

North America Pet

(6) pts

3 pts

(3)%

--

--

7 pts

4%

North America Foodservice

(2) pts

2 pts

Flat

--

(7) pts

6 pts

(1)%

International

1 pt

2 pts

3%

5 pts

--

8 pts

16%

Total

(2) pts

2 pts

Flat

1 pt

(7) pts

7 pts

1%

Full Year

North America Retail

(1) pt

(2) pts

(3)%

--

(9) pts

1 pt

(11)%

North America Pet

(5) pts

2 pts

(3)%

--

6 pts

2 pts

6%

North America Foodservice

(2) pts

1 pt

(1)%

--

(7) pts

2 pts

(6)%

International

2 pts

1 pt

3%

4 pts

--

2 pts

9%

Total

(1) pt

(1) pt

(2)%

1 pt

(6) pts

2 pts

(5)%

  Fiscal 2026 Segment Operating Profit Growth

Fourth Quarter

% Change

as Reported

% Change in

Constant Currency

North America Retail

7%

7%

North America Pet

14%

14%

North America Foodservice

22%

22%

International

81%

72%

Total

13%

13%

Full Year

North America Retail

(20)%

(20)%

North America Pet

Flat

Flat

North America Foodservice

(6)%

(6)%

International

96%

90%

Total

(13)%

(13)%

  North America Retail Segment
Fourth-quarter net sales for General Mills’ North America Retail segment were down 4 percent to $2.5 billion, including a 10-point headwind from divestitures and a 7-point benefit from the 53rd week. Organic net sales essentially matched year-ago results while Nielsen-measured retail sales were down 4 percent, with the gap driven by a previously expected 2-point benefit from trade expense timing as well as a benefit from changes in retailer inventory. Segment operating profit of $506 million increased 7 percent as reported and in constant currency, driven by favorable net price realization and mix and lower selling, general, and administrative (SG&A) expenses, partially offset by lower volume, including the impact of the U.S. yogurt divestiture, and higher input costs. Favorable trade expense timing was a 9-point benefit to operating profit growth in the quarter.

For the full year, North America Retail segment net sales were down 11 percent to $10.6 billion, including a 9-point headwind from divestitures and a 1-point benefit from the 53rd week. Organic net sales were down 3 percent. Increased consumer value, innovation, and product news drove strong pound competitiveness, with the segment holding or gaining pound share in 65 percent of its top 10 U.S. categories. Segment operating profit of $2.2 billion was down 20 percent as reported and in constant currency, due primarily to lower volume, including the impact of the yogurt divestitures, and higher input costs, partially offset by favorable net price realization and mix and lower SG&A expenses.

North America Pet Segment
Fourth-quarter net sales for the North America Pet segment were up 4 percent to $702 million, including a 7-point benefit from the 53rd week. Net sales were up double digits for cat food, up low-single digits for dog food, and down low-single digits for pet treats. Organic net sales were down 3 percent and all-channel retail sales were down approximately 1 percent, with the 2-point gap driven largely by changes in retailer inventory. Segment operating profit of $160 million was up 14 percent as reported and in constant currency, driven primarily by favorable net price realization and mix and lower input costs, partially offset by higher SG&A expenses, including a double-digit increase in media investment.

For the full year, North America Pet segment net sales were up 6 percent to $2.6 billion, including a 6-point benefit from the North American Whitebridge Pet Brands acquisition and a 2-point benefit from the 53rd week. Organic net sales were down 3 percent and lagged all-channel retail sales growth by approximately 4 points. The segment held dollar share in dog feeding and cat feeding, which represented approximately 80 percent of its retail sales. Segment operating profit of $499 million essentially matched year-ago levels, with higher input costs and higher SG&A expenses, including a double-digit increase in media investment, offset by favorable net price realization and mix and higher volume.

North America Foodservice Segment
Fourth-quarter net sales for the North America Foodservice segment were down 1 percent to $575 million, including a 7-point headwind from the U.S. yogurt divestiture and a 6-point benefit from the 53rd week. Organic net sales essentially matched year-ago results, including a 2-point headwind from index pricing on bakery flour. Segment operating profit increased 22 percent to $101 million, driven primarily by Holistic Margin Management (HMM) cost savings and favorable net price realization and mix, partially offset by input cost inflation.

For the full year, North America Foodservice net sales were down 6 percent to $2.2 billion, including a 7-point headwind from the yogurt divestitures and a 2-point benefit from the 53rd week. Organic net sales were down 1 percent, including a 2-point headwind from index pricing on bakery flour. The segment held or gained dollar share in nearly 90 percent of its priority businesses, driven by gains in healthcare, lodging, recreation, and college and university channels. Segment operating profit was down 6 percent to $333 million, driven by the impact of the yogurt divestitures.

International Segment
Fourth-quarter net sales for the International segment increased 16 percent to $858 million, including an 8-point benefit from the 53rd week and a 5-point benefit from foreign currency exchange. Organic net sales were up 3 percent, driven by growth in Brazil, Europe, India, and China. Segment operating profit of $61 million was up 81 percent as reported and up 72 percent in constant currency, driven by favorable net price realization and mix and higher volume, partially offset by higher input costs and higher SG&A expenses.

For the full year, International net sales were up 9 percent to $3.0 billion, including a 4-point benefit from foreign currency exchange and a 2-point benefit from the 53rd week. Organic net sales were up 3 percent. The segment held or gained dollar share in 45 percent of its priority businesses. Segment operating profit of $189 million was up 96 percent as reported and up 90 percent in constant currency, driven by favorable net price realization and mix and higher volume, partially offset by higher input costs and higher SG&A expenses.

Joint Venture Summary
Fourth-quarter constant-currency net sales were down 3 percent for Cereal Partners Worldwide (CPW) and up 12 percent for Häagen-Dazs Japan (HDJ). Combined after-tax loss from joint ventures totaled $18 million in the quarter, compared to a loss of $6 million in the prior year, driven primarily by the company’s share of losses related to the sale of certain assets at CPW. For the full year, after-tax loss from joint ventures totaled $76 million compared to earnings of $58 million a year ago, driven primarily by the company’s share of a non-cash goodwill impairment charge at CPW as well as losses related to the sale of certain assets at CPW.

Other Income Statement Items
Full-year unallocated corporate items totaled $402 million net expense in fiscal 2026 compared to $396 million net expense a year ago (please see Note 4 below for more information on these expenses). Excluding mark-to-market valuation effects and other items affecting comparability, unallocated corporate items totaled $398 million net expense this year compared to $331 million net expense a year ago.

Restructuring, transformation, impairment, and other exit costs totaled $3.0 billion of net expense in fiscal 2026 compared to $78 million of net expense a year ago (please see Note 3 below for more information on these charges).

Net interest expense totaled $539 million in fiscal 2026 compared to $524 million a year ago, driven primarily by the 53rd week. The effective tax rate was 102.2 percent in fiscal 2026 compared to 20.2 percent last year (please see Note 6 below for more information on our effective tax rate), driven primarily by the non-cash goodwill charge in fiscal 2026 that was not deductible for tax purposes. The adjusted effective tax rate was 21.1 percent compared to 20.6 percent a year ago, driven primarily by unfavorable earnings mix by jurisdiction in fiscal 2026, partially offset by certain non-recurring tax benefits in fiscal 2026.

Cash Flow Generation and Cash Returns
Cash provided by operating activities totaled $2.2 billion in fiscal 2026 compared to $2.9 billion a year ago, driven primarily by changes in accounts payable, other current assets, and other current liabilities. Capital investments totaled $540 million compared to $625 million a year ago. Full-year operating cash flow conversion was not meaningful as a percent of after-tax earnings and free cash flow conversion was 85 percent of adjusted after-tax earnings. Dividends paid decreased 2 percent to $1.3 billion, driven by lower average shares outstanding. The company’s share repurchase activity in fiscal 2026 totaled $500 million compared to $1.2 billion in share repurchases a year ago. Average diluted shares outstanding decreased 4 percent in fiscal 2026 to 538 million.

Targeting $3 Billion in Cost Savings by Fiscal 2030
In an effort to help address input cost inflation, fund growth investments, and deliver accelerated profit and cash flow growth, General Mills announced that it expects to generate $3 billion in cumulative cost savings in the four years through fiscal 2030. Roughly $2 billion of this target is expected to be generated through the company’s ongoing HMM productivity program, equating to annual savings of approximately 4 percent of cost of goods sold. The remaining $1 billion is expected to be generated by the company’s global transformation initiative and other cost efficiency efforts, including redesigning the supply chain network, further streamlining business processes, and driving improvement across other elements of its cost base. These efforts will create a more agile and efficient structure that is better fit for future growth. General Mills expects to generate at least $750 million in total savings in fiscal 2027 toward this $3 billion target.

Dividend Declared
The General Mills board of directors declared a quarterly dividend at the prevailing rate of $0.61 per share, payable August 3, 2026, to shareholders of record July 10, 2026. General Mills and its predecessor company have paid dividends without interruption for 127 years.

Fiscal 2027 Outlook
General Mills’ top priority is to restore profitable organic net sales growth over the long term by improving the remarkability of its brands. For fiscal 2027, the company expects category growth to be consistent with recent trends and below its long-term historical growth rate, driven by a continued challenging consumer backdrop. With its base price investment actions completed in fiscal 2026, the company expects to shift its focus in fiscal 2027 to product innovation and renovation news centered on the benefits that matter most to today’s consumers, including better-for-you benefits like protein and fiber, bold flavors, fun and indulgence, and pet humanization. This approach is expected to further strengthen brand remarkability and drive improved organic net sales performance in fiscal 2027.

On the bottom line, General Mills expects to generate at least $750 million in savings from HMM, its global transformation initiative, and other cost savings actions in fiscal 2027, which are expected to offset input cost inflation and sustained investments in brand remarkability. In addition to those factors, the company expects headwinds of approximately 9 points on operating profit and 11 points on EPS in fiscal 2027 from lapping the 53rd week in fiscal 2026, normalizing corporate incentive expense, and the impact of fiscal 2026 divestitures.

Based on the above assumptions, General Mills outlined its full-year financial targets² for fiscal 2027:

Organic net sales are expected to range between down 1.5 percent and up 0.5 percent. Adjusted operating profit is expected to be down 13 percent to down 8 percent in constant currency from the base of $2.8 billion reported in fiscal 2026. Adjusted diluted earnings are expected to be between $3.00 and $3.20 per share, including an immaterial impact from foreign currency exchange. Free cash flow conversion is expected to be approximately 95 percent of adjusted after-tax earnings. The net impact of divestitures, foreign currency exchange, and the 53rd week is expected to reduce full-year reported net sales growth by approximately 2 percent. Foreign currency exchange is not expected to have a material impact on adjusted operating profit growth. 2 Financial targets are provided on a non-GAAP basis because certain information necessary to calculate comparable GAAP measures is not available. Please see Note 7 to the Consolidated Financial Statements below for discussion of the unavailable information.

General Mills will issue pre-recorded management remarks today, July 1, 2026, at approximately 6:30 a.m. Central time (7:30 a.m. Eastern time) and will hold a live, webcasted question and answer session beginning at 8:00 a.m. Central time (9:00 a.m. Eastern time). The pre-recorded remarks and the webcast will be made available at www.generalmills.com/investors.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on our current expectations and assumptions. These forward-looking statements, including the statements under the captions “Targeting $3 Billion in Cost Savings by Fiscal 2030” and “Fiscal 2027 Outlook,” and statements made by Mr. Harmening, are subject to certain risks and uncertainties that could cause actual results to differ materially from the potential results discussed in the forward-looking statements. In particular, our predictions about future net sales, earnings, and cost savings could be affected by a variety of factors, including: imposed and threatened tariffs by the United States and its trading partners; disruptions or inefficiencies in the supply chain; competitive dynamics in the consumer foods industry and the markets for our products, including new product introductions, advertising activities, pricing actions, and promotional activities of our competitors; economic conditions, including changes in inflation rates, interest rates, tax rates, tariffs, or the availability of capital; product development and innovation; consumer acceptance of new products and product improvements; consumer reaction to pricing actions and changes in promotion levels; acquisitions or dispositions of businesses or assets; changes in capital structure; changes in the legal and regulatory environment, including tax legislation, labeling and advertising regulations, and litigation; impairments in the carrying value of goodwill, other intangible assets, or other long-lived assets, or changes in the useful lives of other intangible assets; changes in accounting standards and the impact of critical accounting estimates; product quality and safety issues, including recalls and product liability; changes in consumer demand for our products; effectiveness of advertising, marketing, and promotional programs; changes in consumer behavior, trends, and preferences, including weight loss trends; consumer perception of health-related issues, including obesity; consolidation in the retail environment; changes in purchasing and inventory levels of significant customers; fluctuations in the cost and availability of supply chain resources, including raw materials, packaging, energy, and transportation; effectiveness of restructuring, transformation and cost saving initiatives; volatility in the market value of derivatives used to manage price risk for certain commodities; benefit plan expenses due to changes in plan asset values and discount rates used to determine plan liabilities; failure or breach of our information technology systems; foreign economic conditions, including currency rate fluctuations; and political unrest in foreign markets and economic uncertainty due to terrorism or war. The Company undertakes no obligation to publicly revise any forward-looking statement to reflect any future events or circumstances.

# # #

      Consolidated Statements of (Loss) Earnings and Supplementary Information
GENERAL MILLS, INC. AND SUBSIDIARIES
(In Millions, Except per Share Data) 

  Fiscal Year

2026

% Change

2025

% Change

2024

(Unaudited)

Net sales

$

18,424.6

(5

)

%

$

19,486.6

(2

)

%

$

19,857.2

Cost of sales

12,228.9

(4

)

%

12,753.6

(1

)

%

12,925.1

Selling, general, and administrative expenses

3,388.5

(2

)

%

3,445.8

6

%

3,259.0

Divestitures gain, net

(1,049.4

)

NM

(95.9

)

NM



Restructuring, transformation, impairment, and other exit costs

2,970.8

NM

78.3

(68

)

%

241.4

Operating profit

885.8

(73

)

%

3,304.8

(4

)

%

3,431.7

Benefit plan non-service income

(58.3

)

7

%

(54.4

)

(28

)

%

(75.8

)

Interest, net

538.6

3

%

524.2

9

%

479.2

Earnings before income taxes and after-tax (loss) earnings from joint ventures

405.5

(86

)

%

2,835.0

(6

)

%

3,028.3

Income taxes

414.3

(28

)

%

573.7

(3

)

%

594.5

After-tax (loss) earnings from joint ventures

(76.5

)

NM

57.6

(32

)

%

84.8

Net (loss) earnings, including earnings attributable to noncontrolling interests

(85.3

)

(104

)

%

2,318.9

(8

)

%

2,518.6

Net earnings attributable to noncontrolling interests

2.3

(90

)

%

23.7

8

%

22.0

Net (loss) earnings attributable to General Mills

$

(87.6

)

(104

)

%

$

2,295.2

(8

)

%

$

2,496.6

(Loss) earnings per share — basic

$

(0.16

)

(104

)

%

$

4.12

(5

)

%

$

4.34

(Loss) earnings per share — diluted

$

(0.16

)

(104

)

%

$

4.10

(5

)

%

$

4.31

Dividends per share

$

2.44

2

%

$

2.40

2

%

$

2.36

Fiscal Year

Comparisons as a % of net sales

2026

Basis Pt

Change

2025

Basis Pt

Change

2024

Gross margin

33.6

%

(100

)

34.6

%

(30

)

34.9

%

Selling, general, and administrative expenses

18.4

%

70

17.7

%

130

16.4

%

Operating profit

4.8

%

(1,220

)

17.0

%

(30

)

17.3

%

Net (loss) earnings attributable to General Mills

(0.5

)%

(1,230

)

11.8

%

(80

)

12.6

%

Fiscal Year

Adjusted comparisons as a % of net sales (a):

2026

Basis Pt

Change

2025

Basis Pt

Change

2024

Adjusted gross margin

33.5

%

(100

)

34.5

%

(30

)

34.8

%

Adjusted operating profit

15.3

%

(190

)

17.2

%

(90

)

18.1

%

Adjusted net earnings attributable to General Mills

10.4

%

(160

)

12.0

%

(120

)

13.2

%

  (a) See Note 7 for a reconciliation of these measures not defined by generally accepted accounting principles (GAAP). 

  See accompanying notes to consolidated financial statements. 

        Consolidated Statements of (Loss) Earnings and Supplementary Information
GENERAL MILLS, INC. AND SUBSIDIARIES
(Unaudited) (In Millions, Except per Share Data) 

  Quarter Ended

May 31,

2026

May 25,

2025

% Change

Net sales

$

4,609.6

$

4,556.2

1

%

Cost of sales

3,006.1

3,082.2

(2

)

%

Selling, general, and administrative expenses

888.1

894.3

(1

)

%

Restructuring, transformation, impairment, and other exit costs

2,808.0

75.7

NM

Operating (loss) profit

(2,092.6

)

504.0

NM

Benefit plan non-service income

(12.2

)

(12.8

)

(5

)

%

Interest, net

151.5

139.7

8

%

(Loss) earnings before income taxes and after-tax loss from joint ventures

(2,231.9

)

377.1

NM

Income taxes

(240.4

)

69.1

NM

After-tax loss from joint ventures

(17.6

)

(6.0

)

193

%

Net (loss) earnings, including earnings attributable to noncontrolling interests

(2,009.1

)

302.0

NM

Net (loss) earnings attributable to noncontrolling interests

(1.2

)

8.0

(115

)

%

Net (loss) earnings attributable to General Mills

$

(2,007.9

)

$

294.0

NM

(Loss) earnings per share – basic

$

(3.74

)

$

0.53

NM

(Loss) earnings per share – diluted

$

(3.74

)

$

0.53

NM

Quarter Ended

Comparisons as a % of net sales

May 31,

2026

May 25,

2025

Basis Pt

Change

Gross margin

34.8

%

32.4

%

240

Selling, general, and administrative expenses

19.3

%

19.6

%

(30

)

Operating (loss) profit

NM

11.1

%

NM

Net (loss) earnings attributable to General Mills

NM

6.5

%

NM

Quarter Ended

Adjusted comparisons as a % of net sales (a):

May 31,

2026

May 25,

2025

Basis Pt

Change

Adjusted gross margin

34.2

%

32.7

%

150

Adjusted operating profit

15.3

%

13.7

%

160

Adjusted net earnings attributable to General Mills

11.0

%

8.8

%

220

  (a) See Note 7 for a reconciliation of these measures not defined by generally accepted accounting principles (GAAP). 

  See accompanying notes to consolidated financial statements. 

        Operating Segment Results and Supplementary Information
GENERAL MILLS, INC. AND SUBSIDIARIES
(In Millions) 

  Fiscal Year

2026

% Change

2025

% Change

2024

(Unaudited)

Net sales:

North America Retail

$

10,571.8

(11

)

%

$

11,907.0

(5

)

%

$

12,473.4

International

3,043.8

9

%

2,797.8

2

%

2,746.5

North America Pet

2,613.3

6

%

2,470.8

4

%

2,375.8

North America Foodservice

2,169.5

(6

)

%

2,300.9

2

%

2,258.7

Total segment net sales

$

18,398.4

(6

)

%

$

19,476.5

(2

)

%

$

19,854.4

Corporate and other

26.2

159

%

10.1

NM

2.8

Total net sales

$

18,424.6

(5

)

%

$

19,486.6

(2

)

%

$

19,857.2

Operating profit:

North America Retail

$

2,189.0

(20

)

%

$

2,729.9

(11

)

%

$

3,080.4

International

188.7

96

%

96.4

(23

)

%

125.2

North America Pet

498.8



%

501.0

3

%

485.9

North America Foodservice

333.0

(6

)

%

355.4

13

%

315.5

Total segment operating profit

$

3,209.5

(13

)

%

$

3,682.7

(8

)

%

$

4,007.0

Unallocated corporate items

402.3

2

%

395.5

18

%

333.9

Divestitures gain, net

(1,049.4

)

NM

(95.9

)

NM



Restructuring, transformation, impairment, and other exit costs

2,970.8

NM

78.3

(68

)

%

241.4

Operating profit

$

885.8

(73

)

%

$

3,304.8

(4

)

%

$

3,431.7

  See accompanying notes to consolidated financial statements. 

        Operating Segment Results and Supplementary Information
GENERAL MILLS, INC. AND SUBSIDIARIES
(Unaudited) (In Millions) 

  Quarter Ended

May 31,

2026

May 25,

2025

% Change

Net sales:

North America Retail

$

2,466.6

$

2,559.8

(4

)

%

International

858.4

738.9

16

%

North America Pet

702.4

675.2

4

%

North America Foodservice

574.6

579.4

(1

)

%

Total segment net sales

$

4,602.0

$

4,553.3

1

%

Corporate and other

7.6

2.9

162

%

Total net sales

$

4,609.6

$

4,556.2

1

%

Operating (loss) profit:

North America Retail

$

506.4

$

473.8

7

%

International

61.0

33.7

81

%

North America Pet

160.0

140.1

14

%

North America Foodservice

101.3

83.1

22

%

Total segment operating profit

$

828.7

$

730.7

13

%

Unallocated corporate items

113.3

151.0

(25

)

%

Restructuring, transformation, impairment, and other exit costs

2,808.0

75.7

NM

Operating (loss) profit

$

(2,092.6

)

$

504.0

NM

  See accompanying notes to consolidated financial statements. 

        Consolidated Balance Sheets
GENERAL MILLS, INC. AND SUBSIDIARIES
(In Millions, Except Par Value) 

May 31, 2026

May 25, 2025

(Unaudited)

ASSETS

Current assets:

Cash and cash equivalents

$

453.8

$

363.9

Receivables

1,646.8

1,795.9

Inventories

1,917.9

1,910.8

Prepaid expenses and other current assets

599.8

464.7

Assets held for sale



740.4

Total current assets

4,618.3

5,275.7

Land, buildings, and equipment

3,443.4

3,632.6

Goodwill

14,122.4

15,622.4

Other intangible assets

6,716.9

7,081.4

Other assets

1,115.7

1,459.0

Total assets

$

30,016.7

$

33,071.1

LIABILITIES AND EQUITY

Current liabilities:

Accounts payable

$

3,729.5

$

4,009.5

Current portion of long-term debt

1,053.6

1,528.4

Notes payable

68.4

677.0

Other current liabilities

1,472.8

1,624.0

Liabilities held for sale

449.8

18.4

Total current liabilities

6,774.1

7,857.3

Long-term debt

12,416.0

12,673.2

Deferred income taxes

2,265.8

2,100.8

Other liabilities

1,180.2

1,228.6

Total liabilities

22,636.1

23,859.9

Stockholders’ equity:

Common stock, 754.6 shares issued, $0.10 par value

75.5

75.5

Additional paid-in capital

1,200.9

1,218.8

Retained earnings

20,514.9

21,917.8

Common stock in treasury, at cost, shares of 220.9 and 212.2

(11,900.6

)

(11,467.9

)

Accumulated other comprehensive loss

(2,522.3

)

(2,545.0

)

Total stockholders’ equity

7,368.4

9,199.2

Noncontrolling interests

12.2

12.0

Total equity

7,380.6

9,211.2

Total liabilities and equity

$

30,016.7

$

33,071.1

  See accompanying notes to consolidated financial statements. 

        Consolidated Statements of Cash Flows
GENERAL MILLS, INC. AND SUBSIDIARIES
(In Millions) 

  Fiscal Year

2026

2025

(Unaudited)

Cash Flows - Operating Activities

Net (loss) earnings, including earnings attributable to noncontrolling interests

$

(85.3

)

$

2,318.9

Adjustments to reconcile net earnings to net cash provided by operating activities:

Depreciation and amortization

555.2

539.0

After-tax loss (earnings) from joint ventures

76.5

(57.6

)

Distributions of earnings from joint ventures

39.0

44.6

Stock-based compensation

79.4

91.7

Deferred income taxes

203.2

(120.9

)

Pension and other postretirement benefit plan contributions

(31.7

)

(30.8

)

Pension and other postretirement benefit plan costs

(23.7

)

(12.7

)

Divestitures gain, net

(1,049.4

)

(95.9

)

Restructuring, transformation, impairment, and other exit costs

2,897.7

74.3

Changes in current assets and liabilities, excluding the effects of acquisitions and divestitures

(478.3

)

192.4

Other, net

(16.4

)

(24.8

)

Net cash provided by operating activities

2,166.2

2,918.2

Cash Flows - Investing Activities

Purchases of land, buildings, and equipment

(539.9

)

(625.3

)

Acquisitions, net of cash acquired



(1,419.3

)

Proceeds from divestitures

1,830.2

241.8

Investments in affiliates, net

(31.8

)

13.3

Proceeds from disposal of land, buildings, and equipment

4.8

1.1

Other, net

(5.1

)

(6.5

)

Net cash provided (used) by investing activities

1,258.2

(1,794.9

)

Cash Flows - Financing Activities

Change in notes payable

(608.2

)

667.1

Issuance of long-term debt

2,005.8

2,354.9

Payment of long-term debt

(2,823.3

)

(1,300.0

)

Repurchase of Class A limited membership interests in General Mills Cereals, LLC



(252.8

)

Proceeds from common stock issued on exercised options

0.5

43.0

Purchases of common stock for treasury

(500.3

)

(1,202.9

)

Dividends paid

(1,315.3

)

(1,338.7

)

Distributions to noncontrolling interest holders

(2.1

)

(21.6

)

Other, net

(72.1

)

(129.1

)

Net cash used by financing activities

(3,315.0

)

(1,180.1

)

Effect of exchange rate changes on cash and cash equivalents

18.4

2.7

Increase (decrease) in cash and cash equivalents

127.8

(54.1

)

Cash and cash equivalents - beginning of year

363.9

418.0

Cash and cash equivalents - end of year (includes $37.9 million of cash classified as held for sale as of May 31, 2026)

$

491.7

$

363.9

Cash flow from changes in current assets and liabilities, excluding the effects of acquisitions and divestitures:

Receivables

$

12.9

$

(79.0

)

Inventories

(82.2

)

(18.5

)

Prepaid expenses and other current assets

(147.7

)

80.8

Accounts payable

(186.2

)

86.7

Other current liabilities

(75.1

)

122.4

Changes in current assets and liabilities

$

(478.3

)

$

192.4

  See accompanying notes to consolidated financial statements. 

        GENERAL MILLS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

  (1)

The accompanying Consolidated Financial Statements of General Mills, Inc. (we, us, our, General Mills, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States for annual and interim financial information. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal recurring nature.

Our fiscal year ends on the last Sunday in May. Fiscal year 2026 consists of 53 weeks, while fiscal years 2025 and 2024 consisted of 52 weeks. Our India business is on an April fiscal year end. In addition, the consolidated results of certain recent acquisitions are reported on a one-month lag. Please see Note 2 for more information.

  (2)

During the fourth quarter of fiscal 2026, we entered into a definitive agreement to sell our business in Brazil to Café Três Corações S.A. (3corações) for a base price of R$800 million, subject to certain specified deductions and customary post-closing adjustments. The sale is anticipated to close in calendar 2026, subject to regulatory approvals and other customary closing conditions. As a result, we have classified relevant assets and liabilities (the disposal group) associated with our Brazil business as held for sale in our Consolidated Balance Sheets as of May 31, 2026. Additionally, in the fourth quarter of fiscal 2026, we recorded a $1,032 million non-cash pre-tax loss to value the disposal group at the lower of its carrying value or fair value less costs to sell based on estimated net proceeds, which was based on Level 2 inputs in the fair value hierarchy and includes the impact of accumulated foreign currency translation losses that will be reclassified to earnings upon sale. We recorded the loss in restructuring, transformation, impairment, and other exit costs in our Consolidated Statements of (Loss) Earnings, which consisted of a $753 million reserve against the assets held for sale and a $265 million accrual of the remaining difference between the carrying amount and the estimated net proceeds within liabilities held for sale. We will monitor changes in the estimated net proceeds that could further impact the value of the disposal group and the loss on sale.

  In fiscal 2025 and 2026, we divested our North American yogurt businesses (Divestitures). During the first quarter of fiscal 2026, we completed the sale of our United States yogurt business to Groupe Lactalis S.A. and recorded a pre-tax gain of $1,046 million. During the third quarter of fiscal 2025, we completed the sale of our Canada yogurt business to Sodiaal International and recorded a pre-tax gain of $96 million. In the first quarter of fiscal 2026, we recorded a sale price adjustment that resulted in an $8 million increase to the pre-tax gain.

  During the third quarter of fiscal 2025, we acquired NX Pet Holding, Inc., representing Whitebridge Pet Brands’ North American premium cat feeding and pet treating business, for a purchase price of $1.4 billion (Acquisition). We financed the transaction with cash on hand and new debt. We consolidated Whitebridge Pet Brands into our Consolidated Balance Sheets and recorded goodwill of $1,087 million, an indefinite-lived intangible asset for the Tiki Pets brand totaling $289 million, and a finite-lived customer relationship asset of $31 million. The goodwill is included in the North America Pet segment and is not deductible for tax purposes. The pro forma effects of this acquisition were not material. The consolidated results are reported in our North America Pet operating segment on a one-month lag. In fiscal 2026, we recorded a $32 million decrease to goodwill, primarily related to adjustments to certain purchase accounting liabilities upon finalization of income tax returns recorded in the second quarter of fiscal 2026.

  During the fourth quarter of fiscal 2024, we acquired a pet food business in Europe for a purchase price of $434 million, net of cash acquired. During fiscal 2025, we paid $8 million related to a purchase price holdback after closing conditions were met. We financed the transaction with cash on hand. We consolidated the business into our Consolidated Balance Sheets and recorded goodwill of $318 million, an indefinite-lived brand intangible asset of $118 million, and a finite-lived customer relationship asset of $14 million. The goodwill is included in the International segment and is not deductible for tax purposes. The pro forma effects of this acquisition were not material. The consolidated results of the business are reported as part of our International operating segment on a one-month lag.

  (3)

Restructuring, transformation, and impairment charges are recorded in our Consolidated Statement of (Loss) Earnings as follows:

Quarter Ended

Fiscal Year

In Millions

May 31,

2026

May 25,

2025

2026

2025

2024

Restructuring, transformation, impairment, and other exit costs

$

2,808.0

$

75.7

$

2,970.8

$

78.3

$

241.4

Cost of sales

6.0

8.2

19.4

9.2

17.6

Total restructuring, transformation, and impairment charges

2,814.0

83.9

2,990.2

87.5

259.0

In the second quarter of fiscal 2026, we recorded a $53 million non-cash impairment charge related to our Uncle Toby’s brand intangible asset. 

Additionally, we identified a triggering event due to a sustained decline in market capitalization and stock price in the fourth quarter of fiscal 2026 reflecting heightened macroeconomic uncertainty and lower market multiples in our industry, which caused a related increase in our discount rates and required an interim impairment assessment. We performed the interim impairment assessment of our goodwill and other intangible assets as of May 31, 2026, and determined that the fair values of our North America Pet reporting unit and our Nudges and True Chews brand intangible assets no longer exceeded the carrying values of the respective assets, primarily driven by an increase in the discount rates. As a result, we recorded a $1,500 million non-cash goodwill impairment charge related to our North America Pet reporting unit and $250 million of non-cash impairment charges related to our Nudges and True Chews brand intangible assets, primarily driven by an increase in the discount rates. The $1,500 million goodwill impairment charge is not deductible for tax purposes.

  In fiscal 2024, we recorded a $117 million non-cash goodwill impairment charge related to our Latin America reporting unit and $103 million of non-cash impairment charges related to our Top Chews, True Chews, and EPIC brand intangible assets. 

  In fiscal 2026, we recorded a $1,032 million non-cash pre-tax valuation loss related to the planned divestiture of our Brazil business. Please see Note 2 for additional information. 

  In fiscal 2026, we approved a multi-year organizational initiative to increase the competitiveness of our supply chain. We expect to incur approximately $101 million of restructuring charges related to these actions, of which approximately $33 million will be cash. These charges are expected to consist of approximately $66 million of net asset write-offs and $35 million of other costs, including severance. We recognized $71 million of asset write-offs and $24 million of other costs in fiscal 2026. We expect these actions to be completed by the end of fiscal 2029. 

  (4)

Unallocated corporate expense totaled $113 million in the fourth quarter of fiscal 2026, compared to $151 million in the same period last year. We recorded a $36 million net decrease in expense related to the mark-to-market valuation of certain commodity positions and grain inventories in the fourth quarter of fiscal 2026, compared to an $8 million net increase in expense in the same period last year. In the fourth quarter of fiscal 2026, we also recorded $15 million of transaction costs, primarily related to the definitive agreements to sell our Brazil business, compared to $16 million of transaction costs related to the Divestitures in the fourth quarter of fiscal 2025. We recorded $6 million of restructuring charges in costs of sales in the fourth quarter of fiscal 2026, compared to $8 million of restructuring charges in costs of sales in the fourth quarter of fiscal 2025. Additionally, in the fourth quarter of fiscal 2026, certain compensation and benefits expenses increased compared to the same period last year, including the impact of the 53rd week. 

  Unallocated corporate expense totaled $402 million in fiscal 2026, compared to $396 million last year. In fiscal 2026, certain compensation and benefits expenses increased compared to fiscal 2025, including the impact of the 53rd week. We recorded $19 million of restructuring charges in cost of sales in fiscal 2026, compared to $9 million of charges in cost of sales in fiscal 2025. Additionally, we recorded a $48 million net decrease in expense related to the mark-to-market valuation of certain commodity positions and grain inventories in fiscal 2026, compared to a $16 million net decrease last year. In fiscal 2026, we also recorded $31 million of transaction costs, primarily related to the Divestitures and the definitive agreement to sell our Brazil business, compared to $49 million of transaction costs related to the Divestitures and the Acquisition last year. 

  (5)

Basic and diluted earnings per share (EPS) were calculated as follows: 

Quarter Ended

Fiscal Year

In Millions, Except per Share Data

May 31,

2026

May 25,

2025

2026

2025

2024

Net (loss) earnings attributable to General Mills

- as reported

$

(2,007.9

)

$

294.0

$

(87.6

)

$

2,295.2

$

2,496.6

Capital appreciation paid on Class A Interests in GMC (a)



(10.5

)



(10.5

)



Net (loss) earnings for EPS calculation

$

(2,007.9

)

$

283.5

$

(87.6

)

$

2,284.7

$

2,496.6

Average number of common shares - basic EPS

536.6

548.2

537.7

554.5

575.5

Incremental share effect from: (b) (c)

Stock options



0.6



1.2

1.8

Restricted stock units and performance share units



1.6



1.8

2.2

Average number of common shares - diluted EPS

536.6

550.4

537.7

557.5

579.5

(Loss) earnings per share — basic

$

(3.74

)

$

0.53

$

(0.16

)

$

4.12

$

4.34

(Loss) earnings per share — diluted

$

(3.74

)

$

0.53

$

(0.16

)

$

4.10

$

4.31

  (a) Please see Note 7 for additional information  (b) Incremental shares from stock options, restricted stock units, and performance share units are computed by the treasury stock method. 

(c) During fiscal 2026, we reported a net loss attributable to General Mills. Inclusion of dilutive shares would result in a lower loss per share. As a result, the dilutive shares are considered to be antidilutive and were excluded from the calculation of diluted EPS for fiscal 2026. 

  (6)

The effective tax rate for the fourth quarter of fiscal 2026 was 10.8 percent compared to 18.3 percent for the fourth quarter of fiscal 2025. The 7.5 percentage point decrease was primarily due to certain nonrecurring discrete tax benefits, partially offset by a non-deductible goodwill impairment charge and unfavorable earnings mix by jurisdiction in fiscal 2026. Our adjusted effective tax rate was 12.7 percent in the fourth quarter of fiscal 2026, compared to 19.2 percent in the same period last year (see Note 7 below for a description of our use of measures not defined by GAAP). The 6.5 percentage point decrease was primarily due to certain nonrecurring discrete tax benefits in fiscal 2026, partially offset by unfavorable earnings mix by jurisdiction in fiscal 2026.  

  The effective tax rate for fiscal 2026 was 102.2 percent compared to 20.2 percent in fiscal 2025. The 82.0 percentage point increase was primarily driven by a non-deductible goodwill impairment charge and unfavorable earnings mix by jurisdiction in fiscal 2026, partially offset by certain nonrecurring tax benefits in fiscal 2026. Our adjusted effective tax rate was 21.1 percent, compared to 20.6 percent in fiscal 2025 (see Note 7 below for a description of our use of measures not defined by GAAP). The 0.5 percentage point increase is primarily due to unfavorable earnings mix by jurisdiction in fiscal 2026, partially offset by certain nonrecurring tax benefits in fiscal 2026. 

  (7)

We have included measures in this release that are not defined by GAAP. We believe that these measures provide useful information to investors, and include these measures in other communications to investors. For each of these non-GAAP financial measures, we are providing below a reconciliation of the differences between the non-GAAP measure and the most directly comparable GAAP measure, an explanation of why we believe the non-GAAP measure provides useful information to investors, and any additional material purposes for which our management or Board of Directors uses the non-GAAP measure. These non-GAAP measures should be viewed in addition to, and not in lieu of, the comparable GAAP measure. 

  We provide organic net sales growth rates for our consolidated net sales and segment net sales. This measure is used in reporting to our Board of Directors and executive management and as a component of the Board of Directors’ measurement of our performance for incentive compensation purposes. We believe that organic net sales growth rates provide useful information to investors because they provide transparency to underlying performance in our net sales by excluding the effect that foreign currency exchange rate fluctuations, acquisitions, divestitures, and a 53rd fiscal week, when applicable, have on year-to-year comparability. A reconciliation of these measures to reported net sales growth rates, the relevant GAAP measures, are included in our Operating Segment Results above. 

  Certain measures in this release are presented excluding the impact of foreign currency exchange (constant-currency). To present this information, current period results for entities reporting in currencies other than United States dollars are translated into United States dollars at the average exchange rates in effect during the corresponding period of the prior fiscal year, rather than the actual average exchange rates in effect during the current fiscal year. Therefore, the foreign currency impact is equal to current year results in local currencies multiplied by the change in the average foreign currency exchange rate between the current fiscal period and the corresponding period of the prior fiscal year. We believe that these constant-currency measures provide useful information to investors because they provide transparency to underlying performance by excluding the effect that foreign currency exchange rate fluctuations have on period-to-period comparability given volatility in foreign currency exchange markets. 

  Our fiscal 2027 outlook for organic net sales growth, constant-currency adjusted operating profit and adjusted diluted EPS, and free cash flow conversion are non-GAAP financial measures that exclude, or have otherwise been adjusted for, items impacting comparability, including the effect of foreign currency exchange rate fluctuations, restructuring and transformation charges, transaction and acquisition integration costs, acquisitions, divestitures, mark-to-market effects, and a 53rd week from the prior year. We are not able to reconcile these forward-looking non-GAAP financial measures to their most directly comparable forward-looking GAAP financial measures without unreasonable efforts because we are unable to predict with a reasonable degree of certainty the actual impact of changes in foreign currency exchange rates and commodity prices or the timing or impact of acquisitions, divestitures, and restructuring and transformation actions throughout fiscal 2027. The unavailable information could have a significant impact on our fiscal 2027 GAAP financial results. 

  For fiscal 2027, we currently expect: the net impact from foreign currency exchange rates (based on a blend of forward and forecasted rates and hedge positions), divestitures completed prior to fiscal 2027 and those expected to close in fiscal 2027, and a 53rd week from the prior year to decrease net sales growth by approximately 2 percent; foreign currency exchange rates to have an immaterial impact on adjusted operating profit and adjusted diluted EPS growth; and restructuring and transformation charges and transaction and acquisition integration costs related to actions previously announced to total approximately $80 million to $85 million. 

    Significant Items Impacting Comparability

Several measures below are presented on an adjusted basis. The adjustments are either items resulting from infrequently occurring events or items that, in management’s judgment, significantly affect the year-to-year assessment of operating results.

The following are descriptions of significant items impacting comparability of our results.

Goodwill and other intangible assets impairments
Non-cash goodwill and other intangible assets impairment charges related to our North America Pet reporting unit goodwill and our Nudges, Uncle Toby’s, and True Chews brand intangible assets in fiscal 2026. Non-cash impairment charges related to our Latin America reporting unit goodwill and our Top Chews, True Chews, and EPIC brand intangible assets in fiscal 2024. Please see Note 3.

Divestitures gain, net
Net divestitures gain primarily related to the sale of our United States yogurt business in fiscal 2026 and Canada yogurt business in fiscal 2025. Please see Note 2.

Valuation loss on held for sale business
Non-cash valuation loss related to the planned divestiture of our Brazil business recorded in fiscal 2026. Please see Note 2.

CPW asset impairments. losses, and restructuring charges
CPW non-cash goodwill impairment charge related to the Australian market, and other asset impairment charges and losses related to the sale of certain assets recorded in fiscal 2026. CPW impairment charges related to certain long-lived assets recorded in fiscal 2025. CPW restructuring charges related to previously announced actions recorded in fiscal 2024.

Restructuring and transformation charges
Restructuring and transformation charges related to supply chain actions and previously announced actions recorded in fiscal 2026. Restructuring and transformation charges related to global transformation actions and previously announced restructuring actions in fiscal 2025. Restructuring charges related to commercial strategy restructuring actions and previously announced restructuring actions in fiscal 2024. Please see Note 3.

Mark-to-market effects
Net mark-to-market valuation of certain commodity positions recognized in unallocated corporate items. Please see Note 4.

Transaction costs
Fiscal 2026 transaction costs primarily related to the sale of our United States yogurt business and the definitive agreement to sell our Brazil business. Fiscal 2025 transaction costs related to the sale of our North American yogurt businesses and the Whitebridge Pet Brands acquisition. Transaction costs primarily related to the acquisition of a pet food business in Europe in fiscal 2024. Please see Note 2.

Acquisition integration costs
Integration costs related to the Whitebridge Pet Brands acquisition in fiscal 2025 and the acquisition of a pet food business in Europe in fiscal 2024 recorded in fiscal 2026 and fiscal 2025. Integration costs primarily resulting from the acquisition of TNT Crust in fiscal 2024. Please see Note 2.

Investment activity, net
Valuation adjustments of certain corporate investments in fiscal 2026 and fiscal 2025. Valuation adjustments and the gain on sale of certain corporate investments in fiscal 2024. Please see Note 4.

Capital appreciation paid on GMC Class A Interests
Capital account appreciation attributable and paid to the third-party holder of GMC Class A Interests in fiscal 2025.

Project-related costs
Restructuring initiative project-related costs related to previously announced restructuring actions recorded in fiscal 2025 and fiscal 2024.

Legal recovery
Legal recovery recorded in fiscal 2024.

Product recall, net
Net recoveries recorded in fiscal 2024 related to the fiscal 2023 voluntary recall of certain international Häagen-Dazs ice cream products, net of recoveries.

Adjusted Operating Profit Growth and Related Constant-currency Growth Rate

This measure is used in reporting to our Board of Directors and executive management and as a component of the measurement of our performance for incentive compensation purposes. We believe that this measure provides useful information to investors because it is the operating profit measure we use to evaluate operating profit performance on a comparable year-to-year basis. The measure is evaluated on a constant-currency basis by excluding the effect that foreign currency exchange rate fluctuations have on year-to-year comparability given the volatility in foreign currency exchange rates.

Our adjusted operating profit growth on a constant-currency basis is calculated as follows:

Quarter Ended

Fiscal Year

In Millions

May 31,

2026

May 25,

2025

Change

2026

2025

Change

Operating (loss) profit as reported

$

(2,092.6

)

$

504.0

NM

$

885.8

$

3,304.8

(73

)%

Goodwill and other intangible assets impairments

1,750.0



1,802.9



Divestitures gain, net





(1,049.4

)

(95.9

)

Valuation loss on held for sale business

1,031.8



1,031.8



Restructuring and transformation charges

32.2

83.9

155.5

87.5

Mark-to-market effects

(35.7

)

8.1

(48.4

)

(15.7

)

Transaction costs

14.8

16.2

31.3

49.1

Acquisition integration costs

2.9

6.7

9.5

13.9

Investment activity, net

2.0

3.4

(7.6

)

8.3

Project-related costs



0.1



0.5

Adjusted operating profit

$

705.4

$

622.5

13

%

$

2,811.5

$

3,352.6

(16

)%

Foreign currency exchange impact

1 pt

Flat

Adjusted operating profit growth, on a constant-currency basis

13

%

(16

)%

  Note: Table may not foot due to rounding. 

  For more information on the reconciling items, please refer to the Significant Items Impacting Comparability section above. 

      Adjusted Diluted EPS and Related Constant-currency Growth Rate

This measure is used in reporting to our Board of Directors and executive management. We believe that this measure provides useful information to investors because it is the profitability measure we use to evaluate earnings performance on a comparable year-to-year basis.

The reconciliation of our GAAP measure, diluted EPS, to adjusted diluted EPS and the related constant-currency growth rates follows:

Quarter Ended

Fiscal Year

Per Share Data

May 31,

2026

May 25,

2025

Change

2026

2025

Change

Diluted (loss) earnings per share, as reported

$

(3.74

)

$

0.53

NM

$

(0.16

)

$

4.10

(104

)%

Goodwill and other intangible assets impairments

3.15



3.22



Valuation loss on held for sale business

1.45



1.45



Divestitures gain, net





(1.43

)

(0.15

)

CPW asset impairments, losses, and restructuring charges

0.06

0.03

0.28

0.04

Restructuring and transformation charges

0.04

0.11

0.22

0.12

Mark-to-market effects

(0.05

)

0.01

(0.07

)

(0.02

)

Transaction costs

0.02

0.03

0.04

0.07

Acquisition integration costs

0.01

0.01

0.01

0.02

Investment activity, net





(0.01

)

0.01

Capital appreciation paid on GMC Class A Interests



0.02



0.02

Adjusted diluted earnings per share (a)

$

0.95

$

0.74

28

%

$

3.55

$

4.21

(16

)%

Foreign currency exchange impact

1 pt

Flat

Adjusted diluted earnings per share growth, on a constant-currency basis

27

%

(16

)%

  Note: Table may not foot due to rounding. 

  For more information on the reconciling items, please refer to the Significant Items Impacting Comparability section above. 

(a) During fiscal 2026, we reported a net loss attributable to General Mills. Inclusion of dilutive shares would result in a lower loss per share and was therefore excluded from the calculation of diluted EPS. The inclusion of dilutive shares does not have a significant impact on adjusted diluted EPS and the reconciling items. 

  See our reconciliation below of the effective income tax rate as reported to the adjusted effective income tax rate for the tax impact of each item affecting comparability. 

      Adjusted Earnings Comparisons as a Percent of Net Sales

We believe that these measures provide useful information to investors because they are important for assessing our adjusted earnings comparisons as a percent of net sales on a comparable year-to-year basis.

Our adjusted earnings comparisons as a percent of net sales are calculated as follows:

Quarter Ended

In Millions

May 31, 2026

May 25, 2025

Comparisons as a % of Net Sales

Value

Percent of

Net Sales

Value

Percent of

Net Sales

Gross margin as reported (a)

$

1,603.5

34.8

%

$

1,474.0

32.4

%

Mark-to-market effects

(35.7

)

(0.8

)%

8.1

0.2

%

Restructuring and transformation charges

6.0

0.1

%

8.2

0.2

%

Transaction costs

0.4



%





%

Project-related costs





%

0.1



%

Adjusted gross margin

$

1,574.2

34.2

%

$

1,490.3

32.7

%

Operating (loss) profit as reported

$

(2,092.6

)

(45.4

)%

$

504.0

11.1

%

Goodwill and other intangible assets impairments

1,750.0

38.0

%





%

Valuation loss on held for sale business

1,031.8

22.4

%





%

Restructuring and transformation charges

32.2

0.7

%

83.9

1.8

%

Mark-to-market effects

(35.7

)

(0.8

)%

8.1

0.2

%

Transaction costs

14.8

0.3

%

16.2

0.4

%

Acquisition integration costs

2.9

0.1

%

6.7

0.1

%

Investment activity, net

2.0



%

3.4

0.1

%

Project-related costs





%

0.1



%

Adjusted operating profit

$

705.4

15.3

%

$

622.5

13.7

%

Net (loss) earnings attributable to General Mills as reported

$

(2,007.9

)

(43.6

)%

$

294.0

6.5

%

Goodwill and other intangible assets impairments, net of tax (b)

1,692.5

36.7

%





%

Valuation loss on held for sale business, net of tax (b)

780.8

16.9

%





%

CPW asset impairments, losses, and restructuring charges

29.7

0.6

%

16.7

0.4

%

Restructuring and transformation charges, net of tax (b)

24.9

0.5

%

64.4

1.4

%

Mark-to-market effects, net of tax (b)

(27.5

)

(0.6

)%

6.2

0.1

%

Transaction costs, net of tax (b)

11.4

0.2

%

12.4

0.3

%

Acquisition integration costs, net of tax (b)

2.2



%

6.4

0.1

%

Investment activity, net, net of tax (b)

1.6



%

2.7

0.1

%

Project-related costs, net of tax (b)





%

0.1



%

Adjusted net earnings attributable to General Mills

$

507.6

11.0

%

$

403.0

8.8

%

  Note: Table may not foot due to rounding. 

  For more information on the reconciling items, please refer to the Significant Items Impacting Comparability section above. 

(a) Net sales less cost of sales. 

(b) See reconciliation of adjusted effective income tax rate below for tax impact of each adjustment. 

        Fiscal Year

In Millions

2026

2025

2024

Comparisons as a % of Net Sales

Value

Percent of

Net Sales

Value

Percent of

Net Sales

Value

Percent of

Net Sales

Gross margin as reported (a)

$

6,195.7

33.6

%

$

6,733.0

34.6

%

$

6,932.1

34.9

%

Mark-to-market effects

(48.4

)

(0.3

)%

(15.7

)

(0.1

)%

(39.1

)

(0.2

)%

Restructuring and transformation charges

19.4

0.1

%

9.2



%

17.6

0.1

%

Transaction costs

0.4



%





%





%

Project-related costs





%

0.5



%

2.0



%

Product recall, net





%





%

0.2



%

Adjusted gross margin

$

6,167.0

33.5

%

$

6,727.0

34.5

%

$

6,912.7

34.8

%

Operating profit as reported

$

885.8

4.8

%

$

3,304.8

17.0

%

$

3,431.7

17.3

%

Goodwill and other intangible

assets impairments

1,802.9

9.8

%





%

220.2

1.1

%

Divestitures gain, net

(1,049.4

)

(5.7

)%

(95.9

)

(0.5

)%





%

Valuation loss on held for sale business

1,031.8

5.6

%





%





%

Restructuring and transformation charges

155.5

0.8

%

87.5

0.4

%

38.8

0.2

%

Mark-to-market effects

(48.4

)

(0.3

)%

(15.7

)

(0.1

)%

(39.1

)

(0.2

)%

Transaction costs

31.3

0.2

%

49.1

0.3

%

14.0

0.1

%

Acquisition integration costs

9.5

0.1

%

13.9

0.1

%

0.2



%

Investment activity, net

(7.6

)



%

8.3



%

18.5

0.1

%

Project-related costs





%

0.5



%

2.0



%

Legal recovery





%





%

(53.2

)

(0.3

)%

Product recall, net





%





%

(30.3

)

(0.2

)%

Adjusted operating profit

$

2,811.5

15.3

%

$

3,352.6

17.2

%

$

3,602.7

18.1

%

Net (loss) earnings attributable to General Mills as reported

$

(87.6

)

(0.5

)%

$

2,295.2

11.8

%

$

2,496.6

12.6

%

Goodwill and other intangible assets impairments, net of tax (b)

1,732.5

9.4

%





%

161.8

0.8

%

Valuation loss on held for sale business, net of tax (b)

780.8

4.2

%





%





%

Divestitures gain, net, net of tax (b)

(772.8

)

(4.2

)%

(84.8

)

(0.4

)%





%

CPW asset impairments, losses, and restructuring charges

148.8

0.8

%

23.3

0.1

%

2.0



%

Restructuring and transformation charges, net of tax (b)

119.7

0.6

%

67.2

0.3

%

28.4

0.1

%

Mark-to-market effects, net of tax (b)

(37.3

)

(0.2

)%

(12.1

)

(0.1

)%

(30.1

)

(0.2

)%

Transaction costs, net of tax (b)

24.1

0.1

%

37.8

0.2

%

11.9

0.1

%

Acquisition integration costs, net of tax (b)

7.3



%

11.9

0.1

%

0.2



%

Investment activity, net, net of tax (b)

(5.8

)



%

6.4



%

12.6

0.1

%

Project-related costs, net of tax (b)





%

0.4



%

1.3



%

Legal recovery, net of tax (b)





%





%

(40.3

)

(0.2

)%

Product recall, net, net of tax (b)





%





%

(23.3

)

(0.1

)%

Adjusted net earnings attributable to General Mills

$

1,909.7

10.4

%

$

2,345.4

12.0

%

$

2,621.1

13.2

%

  Note: Table may not foot due to rounding. 

  For more information on the reconciling items, please refer to the Significant Items Impacting Comparability section above. 

(a) Net sales less cost of sales. 

(b) See reconciliation of adjusted effective income tax rate below for tax impact of each adjustment. 

        Constant-currency Segment Operating Profit Growth Rates

We believe that this measure provides useful information to investors because it provides transparency to underlying performance of our segments by excluding the effect that foreign currency exchange rate fluctuations have on year-to-year comparability given volatility in foreign currency exchange markets.

Our segments’ operating profit growth rates on a constant-currency basis are calculated as follows:

Quarter Ended May 31, 2026

Percentage Change in
Operating Profit
as Reported

Impact of Foreign
Currency
Exchange

Percentage Change in
Operating Profit on
Constant-Currency Basis

North America Retail

7 %

Flat

7 %

International

81 %

9 pts

72 %

North America Pet

14 %

Flat

14 %

North America Foodservice

22 %

Flat

22 %

Total segment operating profit

13 %

Flat

13 %

Note: Table may not foot due to rounding.  

  Fiscal Year Ended May 31, 2026

Percentage Change in
Operating Profit
as Reported

Impact of Foreign
Currency
Exchange

Percentage Change in
Operating Profit on
Constant-Currency Basis

North America Retail

(20) %

Flat

(20) %

International

96 %

5 pts

90 %

North America Pet

Flat

Flat

Flat

North America Foodservice

(6) %

Flat

(6) %

Total segment operating profit

(13) %

Flat

(13) %

  Note: Table may not foot due to rounding. 

        Adjusted Effective Income Tax Rate

We believe this measure provides useful information to investors because it presents the adjusted effective income tax rate on a comparable year-to-year basis.

Adjusted effective income tax rates are calculated as follows:

Quarter Ended

May 31, 2026

May 25, 2025

In Millions

(Except Per Share Data)

Pretax (Loss)

Earnings (a)

Income

Taxes

Pretax

Earnings (a)

Income

Taxes

As reported

$

(2,231.9

)

$

(240.4

)

$

377.1

$

69.1

Goodwill and other intangible assets impairments

1,750.0

57.5





Valuation loss on held for sale business

1,031.8

251.0





Restructuring and transformation charges

32.2

7.4

83.9

19.3

Mark-to-market charges

(35.7

)

(8.2

)

16.2

3.7

Transaction costs

14.8

3.4

8.1

1.9

Acquisition integration costs

2.9

0.7

3.4

0.8

Investment activity, net

2.0

0.5

6.7

0.4

Project-related costs





0.1

0.1

As adjusted

566.2

71.7

495.5

95.2

Effective tax rate:

As reported

10.8

%

18.3

%

As adjusted

12.7

%

19.2

%

Sum of adjustments to income taxes

312.3

26.1

Average number of common shares - diluted EPS (b)

$

537.3

$

550.4

Impact of income tax adjustments on adjusted diluted EPS

$

(0.58

)

$

(0.05

)

  Note: Table may not foot due to rounding. 

  For more information on the reconciling items, please refer to the Significant Items Impacting Comparability section above. 

(a) (Loss) earnings before income taxes and after-tax loss from joint ventures. 

(b) During fiscal 2026, we reported a net loss attributable to General Mills. Inclusion of dilutive shares would result in a lower loss per share and was therefore excluded from the calculation of diluted EPS. The inclusion of dilutive shares does not have a significant impact on adjusted diluted EPS and the reconciling items. 

        Fiscal Year Ended

May 31, 2026

May 25, 2025

May 26, 2024

In Millions

(Except Per Share Data)

Pretax

Earnings (a)

Income

Taxes

Pretax

Earnings (a)

Income

Taxes

Pretax

Earnings (a)

Income

Taxes

As reported

$

405.5

$

414.3

$

2,835.0

$

573.7

$

3,028.3

$

594.5

Goodwill and other intangible assets impairments

1,802.9

70.4





220.2

58.4

Divestitures gain, net

(1,049.4

)

(276.6

)

(95.9

)

(11.1

)





Valuation loss on held for sale business

1,031.8

251.0









Restructuring and transformation charges

155.5

35.9

87.5

20.2

38.8

10.4

Mark-to-market effects

(48.4

)

(11.1

)

(15.7

)

(3.6

)

(39.1

)

(9.0

)

Transaction costs

31.3

7.2

49.1

11.3

14.0

2.1

Acquisition integration costs

9.5

2.2

13.9

2.0

0.2

0.1

Investment activity, net

(7.6

)

(1.7

)

8.3

1.9

18.5

5.9

Project-related costs





0.5

0.2

2.0

0.7

Legal recovery









(53.2

)

(12.9

)

Product recall, net









(30.3

)

(7.0

)

As adjusted

$

2,331.2

$

491.4

$

2,882.7

$

594.6

$

3,199.4

$

643.1

Effective tax rate:

As reported

102.2

%

20.2

%

19.6

%

As adjusted

21.1

%

20.6

%

20.1

%

Sum of adjustments to income taxes

$

77.3

$

20.9

$

48.6

Average number of common shares - diluted EPS (b)

538.5

557.5

579.5

Impact of income tax adjustments on adjusted diluted EPS

$

(0.14

)

$

(0.04

)

$

(0.08

)

  Note: Table may not foot due to rounding. 

  For more information on the reconciling items, please refer to the Significant Items Impacting Comparability section above. 

(a) Earnings before income taxes and after-tax (loss) earnings from joint ventures. 

(b) During fiscal 2026, we reported a net loss attributable to General Mills. Inclusion of dilutive shares would result in a lower loss per share and was therefore excluded from the calculation of diluted EPS. The inclusion of dilutive shares does not have a significant impact on adjusted diluted EPS and the reconciling items. 

        Free Cash Flow Conversion Rate

We believe this measure provides useful information to investors because it is important for assessing our efficiency in converting earnings to cash and returning cash to shareholders. The calculation of free cash flow conversion rate and net cash provided by operating activities conversion rate, its equivalent GAAP measure, follows:

In Millions

Fiscal 2026

Net loss, including earnings attributable to noncontrolling interests, as reported

$

(85.3

)

Goodwill and other intangible assets impairments, net of tax

1,732.5

Valuation loss on held for sale business, net of tax

780.8

Divestitures gain, net, net of tax

(772.8

)

CPW asset impairments, losses, and restructuring charges

148.8

Restructuring and transformation charges, net of tax

119.7

Mark-to-market effects, net of tax

(37.3

)

Transaction costs, net of tax

24.1

Acquisition integration costs, net of tax

7.3

Investment activity, net, net of tax

(5.8

)

Adjusted net earnings, including earnings attributable to noncontrolling interests

$

1,912.0

Net cash provided by operating activities

2,166.2

Purchases of land, buildings, and equipment

(539.9

)

Free cash flow

$

1,626.3

Net cash provided by operating activities conversion rate

NM

Free cash flow conversion rate

85

%

  Note: Table may not foot due to rounding. 

  For more information on the reconciling items, please refer to the Significant Items Impacting Comparability section above. 

  See our reconciliation above of the effective income tax rate as reported to the adjusted effective income tax rate for the tax impact of each item affecting comparability. 

      More News From General Mills, Inc.
2026-07-01 11:56 1mo ago
2026-07-01 07:16 1mo ago
General Mills Stock Rises on Earnings and Says It‘s Focusing on Organic Sales Growth
GIS General Mills
FMP Stock News
Original source text
General Mills stock advances after the company's fourth-quarter profit handily tops Wall Street expectations.
2026-07-01 11:56 1mo ago
2026-07-01 07:17 1mo ago
General Mills beats fourth-quarter profit and sales estimates
GIS General Mills
FMP Stock News
Original source text
Packages of Cheerios, a brand owned by General Mills, are seen in a store in Manhattan, New York, U.S., November 12, 2021. REUTERS/Andrew Kelly/File Photo Purchase Licensing Rights, opens new tab

July 1 (Reuters) - General Mills (GIS.N), opens new tab beat fourth-quarter profit and sales estimates ​on Wednesday, as an increase ‌in consumers choosing to eat at home over dining out boosted ​demand for the Cheerios maker's ​pantry staples and breakfast cereals.

The ⁠company's shares, which have declined ​25% so far in 2026, ​were up 3% in premarket trading.

The Reuters Daily Briefing newsletter provides all the news you need to start your day. Sign up here.

Budget-conscious consumers, hurt by still-high inflation and the rising cost ​of living, are increasingly ​eating at home rather than dining out, helping demand ‌for ⁠packaged food makers like General Mills.

On an adjusted basis, the company posted a quarterly profit ​of 95 ​cents ⁠per share. Analysts on average estimated 80 cents ​per share, according to data ​compiled ⁠by LSEG.

The company posted sales of $4.61 billion for the quarter ⁠ended ​May 31, compared ​with an estimated $4.60 billion.

Reporting by Koyena Das ​in Bengaluru; Editing by Joyjeet Das

Our Standards: The Thomson Reuters Trust Principles., opens new tab
2026-07-01 11:56 1mo ago
2026-07-01 07:34 1mo ago
General Mills Swings to Loss, Works to Win Back ‘Challenging' Consumers
GIS General Mills
FMP Stock News
Original source text
General Mills swung to a loss in its fourth quarter, as it aims to gain back business by cutting costs and adding more products in the new fiscal year.
2026-07-01 11:54 1mo ago
2026-07-01 07:00 1mo ago
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Nano-X Imaging Ltd. (NNOX), Peabody Energy Corporation (BTU), and First Solar, Inc. (FSLR) Announced by Holzer & Holzer, LLC
FSLR First Solar
FMP Stock News
Original source text
ATLANTA, July 01, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC reminds investors of the deadline to seek to be appointed lead plaintiff in the following class action lawsuits:

Nano-X Imaging Ltd. (NNOX)

The shareholder class action lawsuit filed against Nano-X Imaging Ltd. (“Nano-X”) (NASDAQ: NNOX) alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material facts between March 31, 2025 and April 17, 2026 regarding the efficiency of Nano-X’s operations and its cash burn. If you purchased Nano-X shares during this time period and suffered a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/nano-x-imaging/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is August 11, 2026.

Peabody Energy Corporation (BTU)

The shareholder class action lawsuit filed against Peabody Energy Corporation (“Peabody Energy”) alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material facts between October 14, 2024 and May 4, 2026 regarding Peabody Energy’s Centurion mine ramp-up and anticipated growth. If you purchased Peabody Energy shares during this time period and suffered a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/peabody-energy/ to learn more.    

The deadline to ask the court to be appointed lead plaintiff in the case is August 24, 2026. 

First Solar, Inc. (FSLR)

The shareholder class action lawsuit filed against First Solar, Inc. (“First Solar”) (NASDAQ: FSLR) alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material facts between February 26, 2025 and February 24, 2026 regarding First Solar’s capacity to manage the impact of U.S. tariff policy on its business. If you purchased First Solar shares during this time period and suffered a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/first-solar/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is August 24, 2026. 

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, https://holzerlaw.com/, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.  

CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]
2026-07-01 11:53 1mo ago
2026-07-01 05:59 1mo ago
Recce Pharmaceuticals bolsters cash position with A$3.67 million tax refund ahead of Phase 3 milestones
PLTR Palantir Technologies
FMP Stock News
Original source text
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has strengthened its balance sheet with the receipt of a A$3.67 million income tax refund from the Australian Taxation Office (ATO), adding further non-dilutive funding as the company advances its synthetic anti-infective pipeline toward key Phase 3 clinical milestones.

The refund relates to the financial year ended June 30, 2025, and comprises A$3.57 million in overseas research and development expenditure, plus A$95,826 in interest paid by the ATO.

The receipt lifts Recce’s pro-forma cash position to about A$33.1 million, up from the previously stated A$29.5 million, leaving the company well placed to progress upcoming clinical, regulatory and commercial licensing activities.

Cash boost follows A$4 million placement The tax refund complements Recce’s recently completed A$4 million placement to institutional, sophisticated and professional investors.

The placement was priced at A$0.40 per share and involved the issue of 10 million new fully paid ordinary shares.

Recce is also preparing to open a share purchase plan (SPP) to eligible shareholders on July 6, 2026, allowing participants to subscribe for up to A$30,000 worth of new shares on the same terms as the placement.

The SPP is targeting up to a further A$4 million before costs, potentially taking total proceeds from the equity raising to A$8 million.

Funding directed to licensing and clinical trials Funds from the placement and SPP will support commercial licensing activity, clinical trials and regulatory-enabling work across Recce’s anti-infective pipeline.

The company has allocated A$3.2 million toward strengthening its position for commercial licensing discussions with a leading Middle Eastern pharmaceutical company, including workstreams designed to support a potential commercial agreement.

A further A$2 million has been set aside for clinical trials targeting areas of significant unmet medical need, including Recce’s Phase 3 diabetic foot infections (DFI) registrational topical clinical trial in Indonesia and a Phase 3 DFI registrational topical clinical trial in Australia for the US Food and Drug Administration.

Funding will also support continuation of the US Department of War Burn Wound Program.

Another A$2 million is allocated to activities enabling Investigational New Drug applications to the FDA and Indonesia’s BPOM, while A$800,000 will be used for general working capital and offer costs.

Further R&D rebate expected Recce expects to receive further non-dilutive funding, including an R&D Tax Incentive rebate from the ATO for the financial year ending June 30, 2026, of about A$7.5 million.

This anticipated rebate, together with current cash reserves and capital raising proceeds, is expected to support the company as it moves toward interim clinical data readouts and broader commercialisation opportunities.

Recce CEO James Graham said the capital raising came at an important stage for the company.

“The capital raising comes at an exciting time for the Recce business, having recently signed a non-binding term sheet with a leading Middle Eastern Pharmaceuticals Company and ahead of interim data readouts in Indonesia which is a positive step towards the potential commercialisation of R327G,” Graham said.
2026-07-01 11:53 1mo ago
2026-07-01 06:51 1mo ago
Resolution Minerals advances Horse Heaven drilling as Golden Gate South program gathers pace
PLTR Palantir Technologies
FMP Stock News
Original source text
Resolution Minerals Ltd (ASX:RML, OTCQB:RLMLF) has completed 16 diamond core holes at the Golden Gate South prospect within its Horse Heaven Antimony-Tungsten-Gold-Silver Project in Idaho, marking strong progress in a major 2026 drill campaign targeting gold and tungsten extensions.

The company said 4,470 metres had been drilled across the completed holes, representing about one-third of the planned 13,700-metre program, with two drill rigs operating on site.

Resolution’s Horse Heaven Antimony-Tungsten-Gold-Silver Project – Relationship of Antimony Ridge (Sb) with Golden Gate (Au) and Golden Gate Tungsten (W). 

Sixteen holes completed Resolution has drilled the holes to planned total depths at Golden Gate South, with the completed holes including HH-GG26-001 to HH-GG26-007 and HH-GG26-010 to HH-GG26-018.

The average hole depth is around 279 metres, with the program designed to test the scale and extent of gold mineralisation along strike and at depth across Golden Gate North and Golden Gate South.

The drilling is also targeting tungsten mineralisation around the historical Golden Gate Tungsten mine and a broader tungsten soil anomaly at Golden Gate South.

Core logged and samples dispatched All core from the completed holes has been logged, with company geologists and contractors recording geology, alteration and mineralisation. The core has also been inspected for scheelite, a tungsten ore mineral, with detailed photographs and interval records taken where scheelite was identified.

Resolution has dispatched two large batches of core samples for multi-element analysis, including all samples from holes HH-GG26-001 to HH-GG26-004.

Craig Lindsay, Resolution’s CEO of US operations, said the company was pleased with the pace of drilling at Golden Gate South.

“I am exceedingly pleased with the drill rate we are achieving at Golden Gate South. All core needs to be carefully logged, including but not limited to lithology, alteration and mineralisation, then appropriately sampled. On this front, we are up to date. We have also submitted two large batches of samples,for which we are certainly looking forward to receiving the results.”

Strategic Idaho location Golden Gate forms part of Resolution’s broader Horse Heaven project in Idaho, immediately adjacent to Perpetua Resources’ recently permitted Stibnite Gold Project, a large antimony-gold development.

The Horse Heaven project comprises 729 US federal lode mining claims covering 14,580 acres, including 719 mining claims and 10 lode mining claims referred to as the Oberbillig Group. The company said the mining claims were understood to be in good standing.

The project area hosts gold, antimony, tungsten and silver mineralisation associated with hydrothermally altered and fractured granodiorites.

Drilling builds on earlier gold hits The current campaign follows previous Golden Gate drilling that delivered broad gold intercepts, including 197.5 metres at 1.26 g/t gold, 265.2 metres at 0.60 g/t gold and 253.0 metres at 1.50 g/t gold.

The 2026 Golden Gate program is designed to define the scale and extent of tungsten and gold mineralisation, starting at Golden Gate South.

The Golden Gate drill program remains ongoing, with up to 45 holes and 13,700 metres of diamond core drilling planned. Resolution said drill hole results would be released on an ongoing basis as the campaign progresses.
2026-07-01 11:53 1mo ago
2026-07-01 06:59 1mo ago
Imugene reports second complete response in azer-cel BTKi cohort
PLTR Palantir Technologies
FMP Stock News
Original source text
Just a day after reporting the first complete response in the concurrent Bruton Tyrosine Kinase inhibitor (BTKi) cohort of its ongoing Phase 1b azer-cel trial, Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has reported a second complete response, adding momentum to an early clinical signal in patients with limited remaining treatment options.

The latest response was recorded in the first mantle cell lymphoma (MCL) patient treated in the azer-cel Phase 1b study. The patient had previously received and failed BTKi therapy before achieving a complete response at the Day 28 assessment. 

Second milestone follows first response The result comes close after Imugene reported its first complete response in the concurrent BTKi cohort, highlighting a second early response in a patient group that has relapsed on or is refractory to BTKi therapy.

To date, four patients have been dosed in the Phase 1b concurrent BTKi cohort, with two evaluable patients both achieving a complete response. Imugene said further updates would be provided as additional data becomes available and the dataset matures. 

Imugene managing director and CEO Leslie Chong said achieving a second complete response in the cohort, including in the first MCL patient treated in the study, further reinforced the company’s belief in azer-cel’s potential for patients who have progressed on BTKi therapy.

“Given the broad use of BTK inhibitors across B-cell malignancies and the limited treatment options available following progression, we believe this concurrent dosing approach represents a highly promising clinical and commercial opportunity for azer-cel,” Chong said. 

Targeting patients with few remaining options MCL is an aggressive B-cell non-Hodgkin lymphoma that typically presents at an advanced stage and remains incurable with standard therapies. BTK inhibitors are an established treatment across relapsed or refractory MCL, but Imugene noted that a significant proportion of patients develop resistance or intolerance over time, leaving them with limited options. 

The concurrent BTKi cohort is evaluating whether dosing azer-cel alongside a BTKi may restore or enhance therapeutic activity in this setting. The global BTKi market reached about US$12 billion in 2025. 

About the trial and azer-cel Azer-cel is Imugene’s off-the-shelf, allogeneic CAR T cell therapy targeting CD19 to treat blood cancers. It is derived from healthy donor T cells and can be administered within days, avoiding the three-to-six-week manufacturing lead time required for autologous CAR T products. 

The Phase 1b study is an ongoing, open-label, multi-centre clinical trial in the US and Australia for CAR T-relapsed and CAR T-naïve patients with a broad range of non-Hodgkin lymphomas, including follicular lymphoma, chronic lymphocytic leukaemia/small lymphocytic lymphoma, marginal zone lymphoma, Waldenstrom macroglobulinemia and mantle cell lymphoma. 

Patient enrolment is ongoing across 10 US and five Australian sites. 
2026-07-01 11:53 1mo ago
2026-07-01 07:25 1mo ago
International Graphite strengthens board and Wogen alliance as placement grows to $4.4 million
PLTR Palantir Technologies
FMP Stock News
Original source text
International Graphite Ltd (ASX:IG6, FRA:H99, OTC:IGRPF) has strengthened its board and strategic investor base with the appointment of Xcelsior Capital chief executive officer Liam Farley as a non-executive director, alongside an increase in its recent placement to $4.4 million.

The appointment brings added investment, commercial and supply chain experience to IG6 at a key point in its development, as the company advances graphite processing operations in Western Australia and Europe. 

Farley’s appointment follows Xcelsior’s cornerstone investment in IG6’s recent $4 million placement, with the company saying the move has also helped attract further European interest.

Incoming non-executive director Liam Farley.

Xcelsior is the investment partner of the Wogen group of companies and specialises in financial support for emerging critical metals and minerals producers. IG6 recently announced an agreement for Wogen Pacific Limited to supply concentrate feedstock and provide product sales and market support for the Collie Micronising Facility in Western Australia. 

The combined developments significantly enhance IG6's access to strategic capital, global markets, supply chain expertise and future growth opportunities across the critical minerals sector. 

“Working in partnership with Wogen, Xcelsior offers a rare combination of funding capability and markets expertise to the critical minerals sector. International Graphite has developed a compelling downstream graphite processing strategy with a clear path to production in Australia and Europe. I am excited to join the Board at this important stage in the Company's development and look forward to working closely with management to accelerate execution of this strategy and identify additional opportunities to build shareholder value,” Farley said:

Strategic experience for next phase Farley founded Xcelsior Capital in 2023 and was previously managing director at Proterra Investment Partners in the US. He brings finance experience across critical minerals, industrial materials and energy, with expertise in strategic investment, international project development and capital structuring. 

“We are delighted to welcome Liam to the Board. He brings an outstanding combination of technical and investment experience and relationships across the international critical minerals sector. Importantly, he shares our long-term vision for building IG6 into a globally significant critical minerals processing business,” IG6 chairman Phil Hearse said.

IG6 executive director Aidan Nania said: “Liam’s appointment, together with Xcelsior’s investment and Wogen’s global trading platform, materially strengthens IG6’s commercial and execution capabilities at a critical stage in the Company’s development, as we progress construction at Collie and move toward a final investment decision for the Alkeemia Joint Venture in Italy.”

Placement increased to $4.4 million IG6 has increased its placement from $4 million to $4.4 million before costs following a further investment commitment from a family office associated with Xcelsior. 

The additional shares will be issued under Tranche 2 of the placement, subject to shareholder approval at a general meeting expected to be held on or around August 3, 2026. 

The money raised will strengthen the company’s balance sheet and support acceleration of the Alkeemia/IG6 joint venture, construction of the Collie Micronising Facility and evaluation of additional strategic growth opportunities. 
2026-07-01 11:53 1mo ago
2026-07-01 07:36 1mo ago
archTIS secures A$3.2 million Defence contract to expand Kojensi platform
PLTR Palantir Technologies
FMP Stock News
Original source text
archTIS Ltd (ASX:AR9, OTCQB:ARHLF) has secured a A$3.2 million contract with the Australian Department of Defence, renewing licensing for its Kojensi Enterprise platform and adding significant application development and maintenance services.

The award, made under archTIS’ existing ICT Provider Arrangement Deed of Standing Offer with Defence, includes A$1.0 million in annual recurring software licences and A$2.2 million in application development and maintenance services.

Kojensi Enterprise is archTIS’ secure collaboration platform for handling sensitive and classified information.

Defence renews Kojensi licence The 12-month contract begins on July 1, 2026, and continues Defence’s use of Kojensi Enterprise, which is deployed on-premises across Defence’s sensitive information collaboration environment.

Defence also has the option to extend the contract by up to two further 12-month periods, at its discretion, while the agreement may be terminated for convenience in line with prior Defence awards.

The contract cements archTIS's position as the incumbent provider of policy-enforced information security software inside Defence’s classified ICT environment, with potential for future licensing growth.

Managing director and CEO Daniel Lai said the award reflected Defence’s commitment to Kojensi and archTIS.

“This win is a commitment from the Australian Department of Defence to invest in Kojensi and archTIS,” Lai said. “Defence has not only renewed Kojensi Enterprise, but they are investing to expand Kojensi.”

Lai added the award built on archTIS’ long-standing relationship with Defence and supported the company’s annual recurring revenue growth strategy.

Secure collaboration platform Kojensi is designed to support secure access, sharing and collaboration of sensitive and classified information in high-security ICT environments. archTIS said the latest award highlighted the platform’s value as a government-certified solution for secure information sharing.

archTIS provides data-centric security solutions for government, defence, enterprise and regulated industries, with products spanning policy-enforced zero trust, attribute-based access controls and data protection across cloud, on-premises and hybrid environments.

The company will continue investing in Kojensi to meet the evolving information security needs of Defence and allied government agencies, positioning the platform for growth in user numbers and deployment sites.

Military contracts In May, the company's NC Protect platform passed the final internal production testing phase with the US Department of Defense (DoD), marking a major step towards potential deployment in high-assurance military environments.

The company also secured a contract with a US and European-based military alliance for its NC Protect platform. The initial award covers more than 2,500 users and is valued at about A$416,000 for the remainder of CY2026, with total potential contract value of about A$1.22 million including extension options.

Progress was also made across the Spirion platform, with archTIS securing a new sale worth about A$145,000 within a 60-day sales cycle to a global IT provider operating across advanced computing, artificial intelligence, high-performance computing and immersive digital platforms.

Meanwhile, NC Protect is being integrated with Mindbreeze InSpire for an existing global manufacturing customer, enabling attribute-based access controls within AI-powered enterprise search and knowledge management workflows.
2026-07-01 11:52 1mo ago
2026-07-01 07:00 1mo ago
Wayfair Schedules Second Quarter 2026 Earnings Release and Conference Call
W WayFair
FMP Stock News
Original source text
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Wayfair Inc. (NYSE:W), the destination for all things home, today announced it will release financial results for its second quarter ending June 30, 2026 before the opening of the market on August 4, 2026.

Wayfair will host a conference call at 8 a.m. ET on Tuesday, August 4 to review results. Investors and participants can register for the webcast in advance here.

The call will also be available via dial-in here. The archived webcast will be available shortly after the call at https://investor.wayfair.com.

About Wayfair

Wayfair is the destination for all things home, and we make it easy to create a home that is just right for you. Whether you're looking for that perfect piece or redesigning your entire space, Wayfair offers quality finds for every style and budget, and a seamless experience from inspiration to installation.

Wayfair Media Relations:
Tara Lambropoulos
[email protected]

Wayfair Investor Relations:
Ryan Barney
[email protected]

SOURCE Wayfair Inc.

Also from this source
2026-07-01 11:52 1mo ago
2026-07-01 06:07 1mo ago
Micron Stock Drops But Memory-Chip Prices Keep Rising
MU Micron Technology
FMP Stock News
Original source text
Micron stock was falling to kick off the third quarter but memory-chip prices were higher in June.
2026-07-01 11:52 1mo ago
2026-07-01 06:53 1mo ago
5 Stock Picks Last Quarter From Wall Street's Most Accurate Analysts
MU Micron Technology
FMP Stock News
Original source text
U.S. stocks settled higher on Tuesday, with the Nasdaq Composite gaining around 1.5% during the session.

The S&P 500 climbed 14.9%, while the Nasdaq surged 21.4% in the second quarter, notching its biggest quarterly gains since the second quarter of 2020. The Dow also climbed 12.9%, notching its best quarter since the fourth quarter of 2022.

Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst’s opinion to trust.

Analyst: Asiya Merchant

Analyst: Matt Bryson

Analyst: Cody Acree

Analyst: Aaron Rakers

Analyst: Timothy Arcuri

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.
2026-07-01 11:52 1mo ago
2026-07-01 07:39 1mo ago
Nike, Alcoa, AMD, Micron, and More Stocks That Explain Today's Market
MU Micron Technology
FMP Stock News
Original source text
The stock market, and technology names in particular, were falling ahead of the open Wednesday after a strong performance in the previous session.
2026-07-01 11:52 1mo ago
2026-07-01 05:10 1mo ago
Intuitive Surgical's Moat Is Getting Stronger. Is This the Closest Thing to a 'Forever' Stock?
ISRG Intuitive Surgical
FMP Stock News
Original source text
You may have come into contact with Intuitive Surgical (ISRG 2.07%) without even realizing it -- for example, if you've had a hernia repair or another type of minimally invasive surgery. Intuitive Surgical is the maker of the world's leading surgical robot, the Da Vinci system, which assists surgeons across many common procedures. This dominance has helped the company deliver earnings growth and stock performance over time.

Intuitive Surgical has an extremely strong moat, or competitive advantage, and it may be getting even stronger. This means the company may not face the threat of competition any time soon -- and this is excellent news for the earnings picture and for investors. Is Intuitive Surgical the closest thing to a "forever" stock? Let's find out.

Image source: Getty Images.

The Da Vinci surgical robot So, first, let's consider the company's flagship product and its path so far. Intuitive Surgical offers the Da Vinci platform in four different versions, from a value-oriented product to the latest update, the Da Vinci 5. This latest Da Vinci includes more than 150 design innovations and 10,000x more computing power than the previous release. The new features offer strengths in areas like surgeon autonomy and operating room workflows. In the first quarter of this year, Da Vinci 5 placements totaled 232 -- that's up from 147 in the year-earlier period, showing momentum for this new product.

Intuitive Surgical's moat is particularly strong for a few reasons. Most surgeons have trained on the Da Vinci system, so we could imagine that they would prefer using this system, one they know well. The Da Vinci also represents a million-dollar purchase for hospitals, so once a hospital has committed to the platform, it likely will aim to stick with it to amortize the investment. Finally, a Da Vinci is deeply integrated into operating room operations, making it time-consuming and costly to switch to an alternate platform.

Now it might surprise you when I say that a new entrant to the market actually makes Intuitive Surgical's moat stronger. Medtronic won clearance late last year for its Hugo system for urologic surgical procedures. Importantly, Medtronic has emphasized that the Hugo may represent another "choice" for these surgeries -- so the company isn't positioning its product as a better option than the Da Vinci.

Today's Change

(

-2.07

%) $

-8.41

Current Price

$

397.56

A broad presence worldwide It's also important to note that Intuitive Surgical's broad presence in operating rooms worldwide and the numerous procedures that may be performed with the Da Vinci further secure its market leadership. So, Medtronic's Hugo does offer hospitals an alternative in urology, but this doesn't represent a threat to the Da Vinci's position. In fact, this highlights the strength of Intuitive Surgical's moat.

In the latest quarter, Intuitive Surgical said it grew its Da Vinci installed base to 11,395 systems, for a 12% increase year over year. Da Vinci procedures worldwide climbed 16%, and this is an important figure because the more hospitals use the platforms, the more the company generates revenue. This is because these hospitals invest in accessories and instruments needed for the procedures.

Where most of Intuitive Surgical's revenue comes from And that leads me to another point to like about Intuitive Surgical. The robotic surgery giant actually makes more of its revenue through accessories and instruments than it does from selling robotic surgical systems. This is positive because it means that every platform sold or leased generates recurring revenue for the company -- and at considerably high levels. For example, in the latest quarter, revenue from accessories and instruments totaled $1.6 billion. That's compared to revenue of $650 million from the sales of systems. And Intuitive Surgical also generates considerable revenue from the sales of service contracts to support the robotic systems. In the quarter, these services represented $433 million in revenue.

All of this means that you can count on a certain steady progression in Intuitive Surgical's earnings growth over time -- and this is set to continue as the company's moat is stronger than ever. In my book, this makes Intuitive Surgical just about as close as you can get to a "forever" stock, or one you may want to hold onto for a lifetime.